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1. Introduction 
1.1 Clinical use of BCG in bladder cancer treatment 
Urothelial carcinoma of the bladder is the second most common urologic neoplasm after 
prostate carcinoma in the United States, with an estimated 70,530 new cases and 14,680 
deaths in 2010 (Jemal et al., 2010). Global prevalence of bladder cancer is estimated at >1 
million and is steadily increasing. At the time of diagnosis, 20-25% of cases are muscle 
invasive (stage T2 or higher) and are typically treated with surgical resection (radical 
cystectomy) (Williams et al., 2010). The remainders are nonmuscle invasive bladder cancer 
(NMIBC) including tumors confined to the epithelial mucosa (Ta), tumors invading the 
lamina propria (T1), and carcinoma in situ (Tis). Transurethral resection of bladder tumor 
(TURBT) is the primary treatment for Ta and T1 lesions. Intravesical therapy is used as 
adjuvant treatment to prevent recurrence and progression of the disese after TURBT and is 
also the treatment of choice for carcinoma in situ. Intravesical administration of bacillus 
Calmette-Guérin (BCG), a live attenuated strain of Mycobacterium bovis widely used as a 
vaccine against tuberculosis, is currently the most common therapy employed for NMIBC. 
Since its advent in 1976 (Morales et al., 1976), BCG has been extensively used to reduce 
recurrence and progression of NMIBC in an attempt to preserve the bladder. BCG therapy 
results in 50-60% effectiveness against small residual tumors and a 70-75% complete 
response rate for carcinoma in situ. Adjuvant intravesical therapy was noted by the 2007 
American Urological Association (AUA) panel to reduce recurrences by 24% and treatment 
with BCG was recommended by the panel. Unfortunately, a high percentage of patients fail 
initial BCG therapy and 40-50% of BCG responders develop recurrent tumors within the 
first 5 years (Williams et al., 2010). In addition, up to 90% of patients experience some sort of 
side effects including, although rare, life-threatening complications such as sepsis. 
According to the AUA’s 2007 clinical practice guidelines, BCG therapy should be initiated 
two to three weeks following TURBT with a classic course consisting of six weekly 
intravesical installations. Lyophilized powder BCG (81 mg corresponding to 1-5 X 108 
colony-forming units of viable mycobacteria) is reconstituted in 50 ml of saline and 
administered via urethral catheter into an empty bladder with a dwell time of 2 hours. 
Maintenance BCG is more effective in decreasing recurrence as compared to induction 
therapy alone. Multiple meta-analyses support BCG maintenance and it is now firmly 
established in clinical practice. The European Association of Urology (EAU) and the AUA 
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recommend one year of maintenance for high risk patients (Hall et al., 2007; Babjuk et al., 
2008). An optimal schedule/duration of therapy has yet to be determined; however, most 
who use maintenance follow some permutation of the Southwest Oncology Group (SWOG) 
program, a 3-week “mini” series given at intervals of 3, 6, 12, 18, 24, 30 and 36 months 
(Lamm et al., 2000). At our own institution, induction (first BCG therapy) is initiated 2 to 3 
weeks following TURBT with 6 weekly installations and a 1-2 hour dwell time. For patients 
with carcinoma in situ, severe dysplasia, Grade 3/high grade or poorly differentiated 
pathology, and/or stage T1 disease, formal restaging under anesthesia is performed 6 weeks 
later including obtaining bilateral upper tract cytology, retrograde pyelograms, 4-5 random 
bladder biopsies, and prostatic urethral biopsies. If this pathology and restaging is negative, 
maintenance cycles may be initiated in 6 weeks. We classify three maintenance cycles A, B 
and C. Maintenance A consists of 3 weekly instillations followed by cystoscopy 6 weeks 
later. Cytology and fluorescence in situ hybridization (FISH) in urine specimens may be 
obtained at this time. If cystoscopy/cytology is negative, maintenance B may be initiated 6 
months after the conclusion of cycle A, again for 3 weekly treatments. Maintenance C is 
initiated 6 months after the conclusion of cycle B. Following cycle C, cystoscopy/cytology is 
repeated every 3 months for 2 years from the original diagnosis at which time it is extended 
to every 6 months for 1 year, and then annually. 
1.2 Mechanism of BCG action 
Since its first therapeutic application in 1976, major efforts have been made to decipher the 
mechanisms through which BCG mediates anti-bladder cancer immunity (Brandau & 
Suttmann, 2007; Alexandroff et al., 2010). During the past decades, many details of the 
molecular and cellular mechanisms involved have been discovered although the exact 
mechanisms of BCG action still remain elusive. It is now accepted that a functional host 
immune system is a necessary prerequisite to successful BCG immunotherapy. It has also 
become clear that the effects of intravesical BCG depend on the induction of a complex 
inflammatory cascade event in the bladder mucosa reflecting activation of multiple types of 
immune cells and bladder tissue cells (Brandau & Suttmann, 2007; Alexandroff et al., 2010). 
After instillation, BCG adheres to fibronectin on the urothelial lining through a fibronectin 
attachment protein (FAP) on BCG (Kavoussi et al., 1990). This interaction  between BCG and 
the urothelium is one of the first and most crucial steps. Attached BCG is then internalized 
and processed by urothelial cells including urothelial carcinoma cells (UCC), resulting in 
secretion of an array of proinflammatory cytokines and chemokines such as interleukin (IL)-
1, IL-6, IL-8, tumor necrosis factor (TNF)-α, and granulocyte-macrophage colony stimulating 
factor (GM-CSF) (Becich et al., 1991; Bevers et al., 2004). Following urothelail cell activation, 
an influx of various leukocyte types into the bladder wall occurs including neutrophils, 
monocytes/macrophages, lymphocytes, natural killer (NK) cells, and dendritic cells (DC) 
(aBöhle et al., 1990; Prescott et al., 1992; aSaban et al., 2007). These infiltrating leukocytes are 
activated and produce a variety of additional proinflammatory cytokines and chemokines 
and also form BCG-induced granuloma structures in the bladder wall (aBöhle et al., 1990; 
aSaban et al., 2007). Subsequently, a large number of leukocyte types such as neutrophils, T 
cells and macrophages are expelled into the bladder lumen and appear in patients' voided 
urine (a-cDe Boer et al., 1991; Simons et al., 2008). In addition, transient massive cytokines 
and chemokines can be detected in voided urine including IL-1β, IL-2, IL-6, IL-10, IL-12, IL-
18, interferon (IFN)-γ, TNF-α, GM-CSF, macrophage colony-stimulating factor (M-CSF), 
macrophage-derived chemokine (MDC), monocyte chemoattractant protein (MCP)-1, 
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macrophage inflammatory protein (MIP)-1α, interferon-inducible protein (IP)-10, monokine 
induced by γ-interferon (MIG), and eosinophil chemoattractant activity (Eotaxin) (bBöhle et 
al., 1990; cDe Boer et al., 1991; De Reijke et al., 1996; Taniguchi et al., 1999; Saint et al., 2002; 
Nadler et al., 2003; Luo et al., 2007). The urine of animals treated with intravesical BCG also 
showed increased IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12, IL-17, IFN-γ, TNF-α, 
GM-CSF, M-CSF, MIP-1α, regulated on activation normal T cell expressed and secreted 
(RANTES), and keratinocyte-derived chemokine (KC) (aSaban et al., 2007). It has been noted 
that the development of a predominant Th1 cytokine profile (e.g. IFN-γ, IL-2 and IL-12) is 
associated with the therapeutic effects of BCG, whereas the presence of a high level of Th2 
cytokines (e.g. IL-10) is associated with BCG failure (De Reijke et al., 1996; Saint et al., 2002; 
Nadler et al., 2003). Thus, a shift of the cytokines produced towards a Th1 milieu is 
necessary for succesful BCG immunotherapy of bladder cancer. To support this, it has been 
observed that both IFN-γ and IL-12 but not IL-10 are required for local tumor surveillance in 
an animal model of bladder cancer (Riemensherger et al., 2002). Mice deficint in IL-10 
genetically (IL-10-/-) or functionally via antibody neutralization can also develop enhanced 
anti-bladder cancer immunity in response to intravesical BCG (Nadler et al., 2003).  
Multiple immune cell types participate in the inflammatory response induced by BCG in the 
bladder. It is well accepted that macrophages, an indispensable cellular component of the 
innate immune system, serve as the first line of defense in mycobacterial infection. 
Activation, maturation and cytokine production of macrophages are primarily induced by 
Toll-like receptor (TLR) 2 ligation (Heldwein et al., 2003). Following BCG instillation, an 
increased number of macrophages can be observed in bladder cancer infiltrates and the 
peritumoral bladder wall. Voided urine after BCG instillation also contains an increased 
number of macrophages and the cytokines and chemokines predominantly produced by 
macrophages such as TNF-α, IL-6, IL-10, IL-12 and IL-18 (bBöhle et al., 1990; a,cDe Boer et al., 
1991; Saint et al., 2002; Nadler et al., 2003; Luo et al., 2007). In addition to presenting BCG 
antigens, both human and murine macrophages are capable of functioning as tumoricidal 
cells toward bladder cancer cells upon activation by BCG in vitro (Pryor et al., 1995; Yamada 
et al., 2000; Luo et al., 2004, 2006, 2010). The killing of bladder cancer cells by macrophages 
relies on direct cell-to-cell contact and release of various soluble effector factors such as 
cytotoxic cytokines TNF-α and IFN-γ and apoptotic mediators such as nitric oxide (NO) 
(Jansson et al., 1998; Luo et al., 2004, 2006, 2010). Th1 cytokines (e.g. IFN-γ) enhance the 
induction of macrophage cytotoxicity whereas Th2 cytokines (e.g. IL-10) inhibit the 
induction of macrophage cytotoxicity (Luo et al., 2006, 2010).  
Neutrophils also compose the early responding cells to BCG instillation of the bladder and 
can be observed in the bladder wall and urine shortly after BCG instillation (a,cDe Boer et al., 
1991; aSaban et al., 2007; Simons et al., 2008). Neutrophils are central mediators of the innate 
immunity in BCG infection and are activated by signalling through TLR2 and TLR4 in 
conjunction with the adaptor protein myeloid differentiation factor 88 (MyD88) (Godaly & 
Young, 2005). In addition to secretion of proinflammatory cytokines and chemokines (e.g. 
IL-1α, IL-1β, IL-8, MIP-1α, MIP-1β, MCP-1, transforming growth factor (TGF)-β, and 
growth-related oncogene (GRO)-α) that lead to the recruitment of other immune cells 
(Suttmann et al., 2006), recent studies revealed that neutrophils are the primary source of 
TNF-related apoptosis-inducing ligand (TRAIL) found in the urine after BCG instillation 
(Ludwig et al., 2004; Kemp et al., 2005). TRAIL is a member of the TNF family that induces 
apoptosis in malignant cells but not in normal cells. Studies have indicated that the 
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neutrophil TRAIL response is specific to BCG stimulation rather than nonspecific immune 
activation. Studies have also revealed a positive correlation between urinary TRAIL level 
and the therapeutic effects of BCG, as BCG responders contained a significant higher 
amount of urinary TRAIL than BCG nonresponders (Ludwig et al., 2004). These 
observations suggest an important role of neutrophils in BCG-induced anti-bladder cancer 
immunity. Indeed, it has been observed that depletion of neutrophils resulted in a reduced 
BCG-induced anti-bladder cancer response in a mouse model of bladder cancer (Suttmann 
et al., 2006).  
Following the activation of macrophages and neutrophils in the bladder wall, driven by 
chemoattractants, recruitment of other immune cell types including CD4+ T cells, CD8+ T 
cells, NK cells, and DC takes place (aBöhle et al., 1990; Prescott et al., 1992). As for 
neutrophils and macrophages, these cell types can be found in the voided urine of patients 
after BCG instillation (a-cDe Boer et al., 1991). These effector cells produce various cytokines 
and chemokines to further promote BCG-induced anti-bladder cancer immune responses in 
the local milieu. In addition, DC, together with macrophages, trigger an anti-BCG specific 
immune response via antigen presentation to T cells that also amplifies the BCG-induced 
antitumor immunity. Like neutrophils and macrophages, both T cells and NK cells are 
cytotoxic toward bladder cancer cells upon activation. They kill target cells via major 
histocompatibility complex (MHC) restricted (e.g. for cytotoxic T lymphocytes (CTL)) 
and/or MHC non-restricted pathways (e.g. for NK cells) (Pryor et al., 1995; Suttmann et al., 
2004; Liu et al., 2009). Perforin-mediated lysis and apoptosis-associated killing (e.g. via Fas 
ligand and TRAIL) have been implicated as the major molecular effector mechanisms 
underlying the eradication of bladder cancer cells. These effector cell types are crucial for 
BCG immunotherapy of bladder cancer, as depletion of these cell types failed to develop 
effective anti-bladder cancer responses in vivo and kill bladder cancer cells in vitro (Ratliff et 
al., 1993; Brandau et al., 2001). 
It has been shown that stimulation of human peripheral blood mononuclear cells (PBMC) by 
viable BCG in vitro leads to the generation of a specialized cell population called BCG-
activated killer (BAK) cells (Böhle et al., 1993; aBrandau et al., 2000). BAK cells are a CD3-
CD8+CD56+ cell population whose cytotoxicity is MHC non-restricted (a,bBrandau et al., 
2000). BAK cells kill bladder cancer cells through the perforin-mediated lysis pathway and 
are effective on lysing NK cell-resistant bladder cancer cells (Böhle et al., 1993; a,bBrandau et 
al., 2000). Macrophages and CD4+ T cells have been found to be indispensable for the 
induction of BAK cell killing activity but have no such activity by themselves (aBrandau et 
al., 2000). Th1 cytokines IFN-γ and IL-2 have also been found to be required for the 
induction of BAK cell cytotoxicity, as neutralizing antibodies specific to these cytokines 
could inhibit BCG-induced cytotoxicity (aBrandau et al., 2000). BAK cells, together with 
lymphokine-activated killer (LAK) cells, a diverse population with NK or T cell phenotypes 
that are generated by IL-2 (Jackson et al., 1992; Shemtov et al., 1995), have been suggested to 
be the major effector cells during intravesical BCG immunotherapy of bladder cancer. Other 
potential cytotoxic effector cells include CD1 restricted CD8+ T cells (Kawashima et al., 
2003), γδ T cells (Higuchi et al., 2009), and natural killer T (NKT) cells (Emoto et al., 1999; 
Higuchi et al., 2009). 
Activation of the innate immune system is a prerequisite for the BCG-induced inflammatory 
responses and the subsequent eradication of bladder cancer by intravesical BCG. In BCG 
instillation, TLRs participate in neutrophil, macrophage and DC maturation and activation. 
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Both TLR2 and TLR4 appear to serve important but distinct roles in the induction of host 
immune responses to BCG or BCG cell-wall skeleton (Heldwein et al., 2003). Like other 
microbes, BCG has surface components called pathogen-associated molecular patterns 
(PAMPs) that are recognized by cells of the innate immune system through TLRs during 
infection (Aderem & Ulevitch, 2000). It is this interaction between TLRs and PAMPs that 
activates the cells of the innate immune system, leading to BCG-induced inflammatory 
responses and subsequent eradication of bladder cancer. It is known that the antitumor 
effect of intravesical BCG depends on its proper induction of a localized Th1 immune 
response. However, a systemic immune response also appears involved in intravesical BCG 
therapy. It has been reported that purified protein derivative (PPD) skin test often converts 
from negative to positive after BCG instillation and the effective treatment is associated with 
the development of delayed-type hypersensitivity (DTH) reaction to PPD (Bilen et al., 2003). 
Animal studies have also demonstrated the importance of DTH in the antitumor activity of 
intravesical BCG therapy (Nadler et al., 2003). Moreover, studies have shown increased 
levels of cytokines and chemokines in the serum (e.g. IL-2, IFN-γ, MCP-1 and RANTES), 
along with production of these cytokines and chemokines in the urine and/or bladder, 
during the course of BCG instillation (Taniguchi et al., 1999; Reale et al., 2002). Furthermore, 
studies have also shown an increase in PBMC cytotoxicity against UCC after BCG instilation 
(Taniguchi et al., 1999).  
In addition to the ability of BCG to elicit host immune responses, evidence supports a 
direct effect of BCG on the biology of UCC. In vitro studies have shown that BCG is anti-
proliferative and even cytotoxic to UCC (Pryor et al., 1995; Pook et al., 2007). However, 
this direct cytocidal effect of BCG is not convincing under physiological conditions in vivo, 
as intravesical BCG showed no therapeutic effect on bladder cancer in animal models with 
different immunodeficiencies (Ratliff et al., 1993; Brandau et al., 2001; Suttmann et al., 
2006). In vitro studies have also shown that BCG can induce UCC expression of cytokines 
and chemokines (e.g. IL-1β, IL-6, IL-8, TNF-α and GM-CSF) (Bevers et al., 2004), antigen-
presenting molecules (e.g. MHC class II, CD1 and B7-1) (Ikeda et al., 2002), and 
intercellular adhesion molecules (e.g. ICAM-1) (Ikeda et al., 2002). Analysis of tumor 
biopsy specimens from bladder cancer patients who underwent intravesical BCG therapy 
further supported the ability of BCG to induce UCC expression of these molecules in vivo 
(Prescott et al., 1992). Moreover, the bladder urothelium of animals treated with 
intravesical BCG showed upregulation of HLA antigens (e.g. MHC class I and II) and 
IFN-γ-induced small GTPase families (e.g. GBPs and p47GTPases) as well as activation of 
canonical signaling pathways (e.g. nuclear factor (NF) κB, axonal guidance, aryl 
hydrocarbon receptor, Wnt/β-catenin, and cAMP) (bSaban et al., 2007). However, 
intravesical BCG treatment also down-regulated urothelial expression of certain 
molecules (e.g. single-spanning uroplakins, SPRR2G, GSTM5, and RSP 19) (bSaban et al., 
2007). Recent studies have revealed that by cross-linking α5β1 integrin receptors BCG 
exerts its direct biological effects on UCC, including activation of the signal transduction 
pathways invovling activator protein (AP) 1, NFκB and CCAAT-enhancer-binding protein 
(C/EBP) (Chen et al., 2002), upregulation of gene expressions such as IL-6 and cyclin 
dependant kinase inhibitor p21 (Chen et al., 2002; Zhang et al., 2007), and cell cycle arrest 
at the G1/S transition (Chen et al., 2005). Although some studies showed the ability of 
BCG to induce apoptosis in UCC (Ping et al., 2010), other studies demonstrated that BCG 
induced no apoptosis or even caused apoptotic resistance in UCC (See et al., 2009). 
www.intechopen.com
 
Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
68
Further studies revealed that BCG induced UCC death in a caspase-independent manner 
(See et al., 2009) and that p21 played an important role in modulating the direct effects of 
BCG on UCC (See et al., 2010). During the past decade, studies have also demonstrated 
that peroxisome proliferator-activated receptor gamma (PPARγ), a member of the steroid 
receptor superfamily of ligand-activated transcription factors, is involved in the 
pathogenesis of bladder cancer (Mylona et al., 2009). PPARγ is a key regulator of 
adipogenic differentiation and its ligands have been found to induce terminal 
differentiation or growth inhibition of various cancer cell types including bladder cancer 
(Mansure et al., 2009). Although there is a discrepancy with regard to its actual role in 
bladder cancer, it appears that the lack of PPARγ expression is associated with bladder 
cancer progression. Recent studies have demonstrated that BCG could directly induce 
PPARγ in UCC both in vitro and in vivo, which may contribute to the antitumor activity of 
BCG (Lodillinsky et al., 2006).  
1.3 Combination of BCG with Th1 cytokines for bladder cancer treatment 
The proper induction of Th1 immunity is required for successful BCG immunotherapy of 
bladder cancer. Since a high percentage of patients do not respond to BCG and the effect of 
BCG is associated with significant toxicity, strategies to combine BCG with recombinant (r) 
Th1 cytokines to enhance BCG therapeutic efficacy while reducing BCG toxicity have been 
employed and studied. Among Th1 cytokines, rIFN-α is most extensively studied and has 
been shown to be safe and tolerable when used intravesically, alone or in combination with 
BCG, in many controlled studies (O’Donnell et al., 2001; Lam et al., 2003; Joudi et al., 2006; 
Nepple et al., 2010; Bazarbashi et al., 2011). The side-effect profile of combination therapy is 
similar to BCG monotherapy including lower urinary tract symptoms such as frequency, 
urgency, dysuria, bladder spasm and hematuria. Systemic fever, flu-like symptoms, and 
myalgias were found in <25% of patients and were self-limited. Benefits have been seen in 
patients with BCG failures (O’Donnell et al., 2001; Lam et al., 2003; Joudi et al., 2006). 
Treatment with low-dose BCG (1/3 or 1/10 the standard dose) combined with rIFN-α 
resulted in 45-53% of patients who had failed prior BCG monotherapy to remain disease free 
at 24-month median follow-up (O’Donnell et al., 2001; Joudi et al., 2006). The benefit in naïve 
patients is currently in question with recent studies showing mixed results. A Phase III 
study suggested no benefit in BCG naïve patients (Nepple et al., 2010). However, no sub-
group analysis was performed for carcinoma in situ or high risk patients. Therefore, it can 
still be concluded that the BCG-rIFN-α combination therapy may provide a benefit to 
patients with high risk disease or carcinoma in situ. Data since the release of the Phase III 
study supports the combination therapy with BCG and rIFN-α in BCG naïve patients 
(Bazarbashi et al., 2011). Thus, more studies are needed to formally determine the effect of 
the combination therapy for BCG naive patients. To date, a combination therapy with BCG 
and rIFN-α2B has been employed, particularly for patients with previous BCG failures, 
those with carcinoma in situ, and the elderly (Joudi et al., 2006). Optimal dose and schedule 
have yet to be defined in controlled trials and debate continues on the subject. At our 
institution, we use the standard dose of TICE BCG plus 50 million units (MU) of rIFN-α2B 
intravesically as induction therapy for BCG naïve patients. For BCG exposed patients, 1/3 
the standard dose of BCG plus 50 MU of rIFN-α2B is utilized. The dose may be lowered for 
those patients experiencing lower urinary tract symptoms or low grade fever. For 
www.intechopen.com
Th1 Cytokine-Secreting Recombinant Bacillus Calmette-Guérin:  
Prospective Use in Immunotherapy of Bladder Cancer 
 
69 
maintenance cycle A, we adjust the BCG dose for week 1 consisting of 1/3 the standard dose 
of BCG plus 50 MU of rIFN-α2B. For weeks 2 and 3, the BCG dose is lowered to 1/10 the 
standard dose plus 50 MU of rIFN-α2B. Maintenance cycles B and C utilize similar 
dosing. 
Other cytokines that have been used intravesically include rIL-2, rIL-12, rIFN-γ and rGM-
CSF. A study demonstrated that intravesical rIL-2 was beneficial for patients with T1 
papillary bladder carcinoma after TURBT showing regression of marker lesions and lack of 
major toxic effects (Den Otter et al., 1998). Other studies also demonstrated intravesical rIL-2 
to be feasible, safe and effective in patients with NMIBC who were untreated or had failed 
prior intravesical therapy with other agents (Tubaro et al., 1995; Ferlazzo et al., 1996). A 
study demonstrated that intravesical rIL-12 was well tolerated by patients with recurrent 
NMIBC but showed no clinically relevant antitumor and immunologic effects (Weiss et al., 
2003). However, the maximum tolerated dose of rIL-12 was not reached in the study. 
Different from human studies, animal studies showed encouraging results. A survival 
advantage of intravesical rIL-12 was observed in a mouse orthotopic bladder cancer model 
(Zaharoff et al., 2009). Further studies for intravesical rIL-12 use are warranted. For 
intravesical rIFN-γ, a study showed the absence of major toxicity and the therapeutic effect 
superior to mitomycin C for patients with NMIBC who underwent TURBT (Giannopoulos et 
al., 2003). In addition, populations of leukocytes in the urothelium were significantly 
increased in rIFN-γ treated patients confirming its induction of localized cellular immune 
responses. Other studies also supported the safety and antitumor activity of intravesical 
rIFN-γ monotherapy (Stavropoulos et al., 2002). Studies also demonstrated that intravesical 
rGM-CSF was effective as a prophylactic therapy for patients with NMIBC after TURBT 
(Stravoravdi et al., 1999; Theano et al., 2002). In correlation with regression of marker 
lesions, intravesical rGM-CSF induced leukocyte migration and activation in the bladder 
mucosa. Despite all these observations, however, single cytokine therapy has only been 
evaluated in small numbers of patients and has not yet shown compelling results in general. 
Indeed, in vitro studies have demonstrated that cytokines IL-2, IL-12 and TNF-α, like IFN-α, 
can enhance BCG for the induction of Th1 immune responses in human PBMC (Luo et al., 
1999, 2003; O’Donnell et al., 1999). Thus, addition of these cytokines to BCG may provide 
benefits for BCG therapy particularly for BCG nonresponders or relapsers. Studies are 
absolutely needed to exame the combination of BCG with these cytokines for the treatment 
of bladder cancer. 
2. Advances in genetic engineering of BCG for cytokine delivery 
2.1 BCG as a heterologous gene delivery vehicle 
Because of its unique characteristics, such as adjuvant potential, low toxicity and potent 
immunogenecity, BCG has long been considered to be an attractive live vaccine delivery 
vehicle with which to deliver protective antigens of multiple pathogens. During the past 2 
decades, with advances in knowledge of mycobacterial genetics and molecular biology, a 
wide range of recombinant BCG (rBCG) vaccine candidates expressing bacterial, viral, 
parasitic antigens have been developed including those for Mycobacterium tuberculosis (M.tb), 
human immunodeficiency virus (HIV), and hepatitis B and C viruses  (Bastos et al., 2009). 
As early as in the 1980s, studies showed that mycobacteria were capable of delivering 
foreign genes that were introduced into the microbes (Jacobs et al., 1987; Snapper et al., 
1988). In the early 1990s, vectors carrying strong promoters from the mycobacterial major 
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heat-shock protein genes (e.g. hsp60 and hsp70) and unique cloning sites, which allowed 
extrachromosomal or integrative expression of foreign antigens, were developed (Stover et 
al., 1991; Lee et al., 1991). Using these expression vectors, BCG was further demonstrated to 
be an effective live delivery vehicle for foreign antigens (Stover et al., 1991, 1993; Aldovini & 
Young, 1991; Connell et al., 1993; a,bLangermann et al., 1994). These rBCG strains 
constitutively expressed foreign antigens and elicited long-lasting specific humoral and/or 
cellular immune responses in mice. Some of these rBCG strains even generated protective 
immunity against respective pathogens whose antigens were expressed by mycobacteria 
such as the outer surface protein A (OspA, Borrelia burgdorferi) (Stover et al., 1993), surface 
proteinase gp63 (Leishmania spp) (Connell et al., 1993), and surface protein A (Streptococcus 
pneumoniae) (aLangermann et al., 1994). Since the vectors used contained no signal sequence, 
the foreign antigens were expressed in the cytoplasm of mycobacteria. During that time 
period, vectors permitting surface expression of foreign antigens in mycobacteria or 
secretion from mycobacteria were developed (Matsuo et al., 1990; Stover et al., 1993). 
Infection with these rBCG strains led to enhanced immune responses to some antigens in 
mice (Stover et al., 1993; aLangermann et al., 1994; Grode et al., 2002). Meanwhile, vectors 
with various mycobacterial gene promoters, such as α-antigen, PAN, ag85b, 18kDa and furA 
(among many others), were also developed and demonstrated to be effective to elicit specific 
immune responses and/or protective immunity in different animal species including 
mouse, guinea pig, hamster, pig, sheep, rabbit, and monkey (Matsuo et al., 1990; Murray et 
al., 1992; Honda et al., 1995; Horwitz et al., 2000; Bastos et al., 2009). In addition, progress 
has continued in the refinement of the safety and efficacy of the rBCG vaccine vehicles. To 
date, numerous improved systems employed to express heterologous genes in BCG are 
available. Among them are vectors with limited replication or auxotrophic complementation 
for safe use in HIV-infected individuals, capability to replicate at a high-copy number for 
increased antigen delivery, dual expression cassettes for multivalent antigen delivery, 
capability to integrate into the genome at multiple sites for differential antigen expression, 
inducible elements for controlled gene expression, and expression of perfringolysin or 
listeriolysin (with or without urease C gene deletion) for increased CD8+ T cell stimulation. 
Although clinical use of rBCG vaccines is still in an early stage, studies have already 
demonstrated that rBCG is safe and effective in humans such as those expressing OspA and 
M.tb antigen 85B (Ag85B). In the years to come, more rBCG vaccines will be evaluated 
clinically and their usefulness in preventing human infectious dieases will become clear.     
In addition to a wide range of bacterial, viral and parasitic antigens, BCG has also been 
engineered to deliver tumor-associated antigens. For example, BCG expressing prostate 
specific molecules such as prostate specific antigen (PSA) and prostate specific membrane 
antigen (PSMA) have been developed. Mice immunized with the rBCG-PSA or rBCG-PSMA 
strain developed antigen-specific immune responses, primarily a cellular immune response 
(Geliebter, 2010). We also independently developed a rBCG strain that secretes the full–
length PSA. We observed that mice immunized with the rBCG-PSA strain, but not a control 
BCG strain carrying an empty vector, developed a potent specific CTL activity against PSA 
expressing RM11psa cells (our unpublished observations). In addition, we further observed 
that mice primed with the rBCG-PSA strain and boosted with Ad-PSA, a replication-
defective adenoviral vector carrying the full-length PSA coding sequence (Elzey et al., 2001), 
developed enhanced PSA-specific CTL activity and IFN-γ expressing CD4+ and CD8+ T cells 
(our unpublished observations). Several studies including ours have also demonstrated that 
BCG could be engineered to express mucin-1 (MUC1), a candidade tumor-associated 
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antigen for breast cancer and other epithelial adenocarcinomas, in a manner of multiple 
tandem repeats with coexpression of IL-2, GM-CSF or CD80 (He et al., 2002; Chung et al., 
2003; a,bYuan et al., 2009, 2010). Severe combined immunodeficient (SCID) mice 
reconstituted with human peripheral blood lymphocytes (PBL) followed by immunization 
with these MUC1 expressing rBCG strains developed specific protective immunity against 
MUC1-positive human breast cancer xenografts. These observations warrant further studies 
in rBCG delivering tumor antigens for the treatment of malignant diseases.  
Studies have shown that BCG delivery of certain biologically active molecules can induce 
enhanced immune responses. A study demonstrated that a rBCG strain secreting cathepsin 
S, a cysteine endoprotease involving in MHC class II antigen presentation, could restore 
intracellular cathepsin S activity and improve the capacity of BCG-infected macrophages to 
stimulate CD4+ T cells (Soualhine et al., 2007). A study also demonstrated that mice 
simultaneously immunized with intraperitoneal ovalbumin (OVA) and intranasal rBCG 
secreting the assembled pentameric cholera toxin B subunit developed a long-lasting OVA-
specific mucosal IgA response as well as a systemic IgG response (Biet et al., 2003). 
Remarkably, a rBCG strain expressing the genetically detoxified S1 subunit of pertussis 
toxin (S1PT) showed enhanced BCG adjuvant potential and, when administered 
intravesically, resulted in bladder weight reduction and increased survival time in a mouse 
syngeneic orthotopic tumor model (Chade et al., 2008; Andrade et al., 2010). Moreover, BCG 
has also been engineered to express the model antigen OVA for studies of the mechanisms 
underlying BCG induction of antigen-specific immune responses (van Faassen et al., 2004). 
These studies revealed that the ability of BCG to induce a delayed but persistent immune 
response was due to its chronicity in infection that led to a long effector phase and reduced 
immune cell attrition compared to Listeria monocytogenes (an acute pathogen). Furthermore, 
we and others have also engineered BCG to express green fluorescent protein (GFP), either 
alone or in combination with antigenic molecules (e.g. OVA) or cytokines (e.g. IL-2), for the 
studies of BCG trafficking, antigen deliver, and anti-mycobacterial infection (Luo et al., 1996, 
2000; Hulseberg et al., 2010).  
2.2 Th1 cytokine-secreting rBCG 
In our early studies, we developed a panel of rBCG strains that secreted mouse IL-2 or rat 
IL-2 under the control of the mycobacterial hsp60 promoter and α-antigen signal sequence 
(O’Donnell et al., 1994). We demonstrated that the IL-2 secreting rBCG strains induced 
enhanced IFN-γ production by mouse splenocytes in vitro compared to wild-type BCG. 
Since then, numerous rBCG strains secreting different mouse and human cytokines, 
primarily Th1 cytokines (e.g. IL-2, IL-18, IFN-γ and IFN-α), have been developed (Table 1). 
In addition, rBCG strains secreting other cytokines or chemokines (e.g. GM-CSF, IL-15, TNF-
α and MCP-3) have also emerged. Most of these cytokine- and chemokine-secreting rBCG 
strains showed their abilities to enhance BCG-induced cellular immune responses including 
Th1 cytokine production, cellular cytotoxicity, DC activation, and anti-BCG or anti-M.tb 
infection. Some of them even showed their antitumor effects in animal models of melanoma 
(Duda et al., 1995), breast cancer (Chung et al., 2003; aYuan et al., 2009, Yuan et al., 2010), 
and bladder cancer (Arnold et al., 2004). Certain cytokine-secreting rBCG strains also 
induced humoral immune responses and Th2 cytokine production other than cellular 
immune responses in vitro and in vivo. 
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Table 1. Cytokine- and chemokine-expressing rBCG strains (Anti-BCG: anti-BCG infection; 
Anti-M.tb: anti-Mycobacterium tuberculosis infection; CI: cellular immunity; DC act: dendritic 
cell activation; h: human; HI: humoral immunity; m: mouse; r: rat; Th1 cyt prod: T helper 
type 1 cytokine production; Th2 cyt prod: T helper type 2 cytokine production) 
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3. Application of Th1 cytokine-secreting rBCG 
3.1 Anti-tuberculosis studies 
Tuberculosis (TB), an airborne transmitted disease caused by M.tb, remains a leading cause 
of mortality and morbidity worldwide. Currently, BCG is the only available vaccine for 
prophylaxis against TB. Evidence indicates that BCG vaccine is effective for childhood 
disseminated TB but shows variable efficacy in adult pulmonary TB, which accounts for 
most TB worldwide. Additional challenges to TB control include the recent emergences of 
multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) as well as TB 
co-infection with HIV. Therefore, a new and more effective vaccine against TB is urgently 
needed. Studies have demonstrated that cellular immunity rather than humoral immunity is 
critical for TB protection (Flynn & Chan, 2001; Mittrücker et al., 2007). CD4+ T cells of Th1 
type, which is a major source of IFN-γ, are crucial for protection against TB. In addition, 
CD8+ T cells also play an indispensable role in control of TB, particularly as the infection 
progresses. With the advances in mycobacterial genome research, many strategies have 
become available for improving BCG’s safety, immunogenecity and vaccine efficacy. Of 
them, genetic manipulation of BCG has gained a great momentum. To date, BCG has been 
engineered to express M.tb antigens, such as the early secreted antigen target-6 kDa (ESAT-
6), Ag85B and culture filtrate protein (CFP), to evoke anti-TB specific immune responses 
(Horwitz et al., 2000; Pym et al., 2003). In addition, rBCG strains secreting cytokines (e.g. IL-
2, IL-15, IL-18, GM-CSF and IFN-γ) or chemokines (e.g. MCP-3), alone or in combination 
with M.tb antigens, have also been developed (Table 1). These cytokine- and chemokine-
secreting rBCG strains can induce a more rapid and more effective mobilization of T cells as 
well as other immune cell types at the site of bacterial multiplication and thus may reduce 
the risk of developing active TB. 
Several studies including ours demostrated that mice infected intravenously with rBCG 
strains secreting mouse IL-2 exhibited significantly reduced bacterial growth in vivo 
compared to control mice infected with non-cytokine secreting BCG strains (Luo et al., 2000; 
bYoung et al., 2002). This anti-mycobacterial infection was correlated with the induction of 
enhanced Th1 immune responses in the former mice. Mice vaccinated subcutaneously with 
a mouse IL-2 secreting rBCG strain also showed significantly increased clearance of BCG 
delivered intranasally compared to control mice vaccinated with wild-type BCG (bYoung et 
al., 2002). The same rBCG strain also induced a Th1 biased immune response in deer; 
however, it failed to induce enhanced protection against BCG infection in this animal 
species (Slobbe et al., 1999). Interestingly, human IL-2 secreting rBCG strains are also 
capable of inducing protective immunity against BCG infection in mice, as mice infected 
with the rBCG strains exhibited increased bacterial clearance in vivo (Kong & Kunimoto, 
1995; Fan et al., 2006). In addition, mice infected with a rBCG strain coexpressing human IL-
2 and M.tb antigen ESAT-6 developed enhanced antigen-specific Th1 immune responses 
including CTL activity against ESAT-6 expressing target cells (Fan et al., 2006). The same 
rBCG-infected mice also developed increased ESAT-6 specific antibody titer. Similar to IL-2 
secreting rBCG strains, mouse IFN-γ secreting rBCG strains showed their abilities to induce 
enhanced protective immunity in rBCG-infected mice compared to non-cytokine secreting 
BCG (Wangoo et al., 2000; Moreira et al., 2000). Studies also demonstrated that infection of 
IFN-γ gene disrupted mice (IFN-γ-/-) via aerosol with a mouse IFN-γ secreting rBCG strain 
could result in reduced bacterial load and better differentiated granulomas as well as 
reduced levels of IL-10 mRNA (Moreira et al., 2000). However, the same rBCG-infected IFN-
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γ-/-mice failed to develop effective protection against subsequent aerosol challenge with 
M.tb. Similarly, a rBCG strain secreting mouse MCP-3 also offorded effective protection 
against BCG infection in both immunocompetent and recombinase-activating gene-1 
deficient (RAG-1-/-) mice but failed to provide protection against subsequent aerosol 
challenge with M.tb (bRyan et al., 2007). There is a discrepancy with regard to the effect of 
mouse IL-18 secreting rBCG starins on the induction of protective immunity against BCG 
infection. Although studies including ours have demonstrated that mouse IL-18 secreting 
rBCG strains could induce enhanced Th1 immune responses (Biet et al., 2002, 2005; Luo et 
al., 2004, 2006), their ability to induce protection against BCG infection was not consistent 
among the studies (Biet et al., 2002, 2005; bYoung et al., 2002; Luo et al., 2004).  
Studies have demonstrated that certain cytokine-secreting rBCG strains can provide 
enhanced protection against dissemination of M.tb infection in mice including those 
secreting mouse GM-CSF (aRyan et al., 2007), mouse IFN-γ fused to M.tb antigens Ag85B-
ESAT-6 (Xu et al., 2007), and mouse IL-15 fused to M.tb antigen Ag85B (Tang et al., 2008). In 
correlation with enhanced protection against aerosol challenge with M.tb, mice vaccinated 
with the mouse GM-CSF secreting rBCG strain showed increased activation of antigen-
presenting cells (e.g. DC) and frequency of anti-mycobacterial IFN-γ producing T cells 
compared to control mice vaccinated with non-cytokine secreting BCG (aRyan et al., 2007). 
Mice vaccinated with the rBCG strain coexpressing mouse IFN-γ and the highly 
immunogenic antigens Ag85B and ESAT-6 of M.tb developed significantly increased both 
cellular and humoral immune responses as well as enhanced protection against intravenous 
challenge of M.tb compared to control mice vaccinated with rBCG strains expressing Ag85B 
and/or ESAT-6 alone (Xu et al., 2007). Similarly, mice vaccinated with the rBCG strain 
coexpressing mouse IL-15 and Ag85B showed increased induction of antigen-specific CD4+ 
and CD8+ T cells as well as enhanced protection against intratracheal challenge of M.tb 
compared to control mice vaccinated with a rBCG strain expressing Ag85B alone (Tang et 
al., 2008). These cytokine-secreting rBCG strains merit further appraisal as vaccine 
candidates for the control of TB in humans. 
3.2 Anti-tumor studies 
BCG is a potent immunoadjuvant and induces a Th1 predominant immune response that is 
required for effective tumor eradication in most cancer types. Genetic manipulation of BCG 
to secrete Th1-stimulating cytokines with simultaneous coexpression of tumor-associated 
antigens may therefore potentiate the induction of specific antitumor immune responses. 
This strategy has been approached since the emergence of cytokine-secreting rBCG strains 
in the 1990s. Early studies demonstrated that mouse IL-2 secreting rBCG was at least equally 
effective to wild-type BCG when used as an intratumoral injection or a vaccine therapy in 
conjunction with irradiated tumor cells in a mouse melanoma model (Duda et al., 1995). 
However, it was not until recently that the potential of rBCG for treating cancer has gained 
further appreciation. We and others have developed rBCG strains that deliver the breast 
cancer-associated antigen MUC1 in a form of multiple tandem repeats with coexpression of 
human IL-2 or human GM-CSF (He et al., 2002; Chung et al., 2003; aYuan et al., 2009, 2010). 
SCID mice reconstituted with human PBL followed by immunization with the rBCG strains 
developed MUC1-specific cellular immune respnses and enhanced protection against 
MUC1-positive human breast cancer xenografts compared to control mice reconstituted 
with human PBL and immunized with non-cytokine secreting BCG. Studies have also 
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demonstrated that the antitumor effects of the rBCG strains were correlated with the 
number of MUC1 tandem repeats delivered by BCG (aYuan et al., 2009, 2010). These results 
suggest that these MUC1 rBCG strains coexpressing Th1-stimulating cytokines are 
promising candidates as breast cancer vaccines and thus deserve further investigation. 
3.3 Anti-bladder cancer studies 
Intravesical BCG is currently the treatment of choice for NMIBC. As for most other cancer 
types, the proper induction of a cellular immune response is required for successful BCG 
immunotherapy of bladder cancer. As described in sections 3.1 and 3.2, Th1 cytokine-
secreting rBCG strains can induce enhanced cellular immune responses, leading to effective 
protection against mycobacterial infection (e.g. M.tb) and tumor progression (e.g. breast 
cancer) in various animal models. Unfortunately, studies on rBCG for treating bladder 
cancer are currently underdeveloped and, up to date, only a few reports have been 
available. However, studies have demonstrated that Th1 cytokine-secreting rBCG strains are 
superior to non-cytokine secreting BCG for the induction of anti-bladder cancer immune 
responses in vitro and in vivo.   
3.3.1 In vitro studies 
It has been known that BCG stimulation of human PBMC leads to the generation of effector 
cells cytotoxic to bladder cancer cells in vitro (Böhle et al., 1993; aBrandau et al., 2000). We 
recently demonstrated that stimulation of human PBMC with rBCG-IFN-α, a rBCG strain 
secreting human IFN-α2B (Luo et al., 2001), in vitro for 7 days induced enhanced PBMC 
cytotoxicity toward human bladder cancer cell lines T24, J82, 5637, TCCSUP and UMUC-3 
by up to 2-fold compared to control BCG carrying an empty vector (Liu et al., 2009). This 
induction of enhanced PBMC cytotoxicity was correlated with increased production of IFN-
γ and IL-2 by rBCG-stimulated PBMC. Studies further revealed that this enhancement in 
PBMC cytotoxicity was dependent on BCG secreted rIFN-α as well as endogenously 
expressed IFN-γ and IL-2, as blockage of IFN-α, IFN-γ or IL-2 by neutralizing antibodies 
during BCG stimulation reduced or abolished the induction of this enhanced PBMC 
cytotoxicity. Studies using NK and CD8+ T cells isolated from human PBMC revealed that 
both cell types were responsible for the enhanced PBMC cytotoxicity induced by rBCG-IFN-
α with the former cell type being more predominant.  
An early study demonstrated that human peripheral monocytes/macrophages were capable 
of functioning as tumoricidal cells toward bladder cancer UCRU-BL-17 cells upon activation 
by BCG in vitro (Pryor et al., 1995). It was observed that the cytotoxic activity of human 
monocytes/macrophages was significantly enhanced after BCG stimulation, while the naïve 
cells exhibited only minimum cytotoxicity. Later, more studies including ours further 
demonstrated that mouse macrophages could also function as tumoricidal cells toward 
bladder cancer cells upon activation by BCG in vitro (Yamada et al., 2000; Luo et al., 2004, 
2006, 2010). Stimulation of thioglycollate-elicited peritoneal macrophages by BCG for 24 
hour resulted in macrophage-mediated killing of bladder cancer MBT-2 (C3H background) 
and MB49 (C57BL/6 background) cells in a dose-dependent manner (Luo et al., 2006, 2010). 
Studies also revealed that endogenous Th1 cytokines (e.g. IL-12, IL-18, IFN-γ and TNF-α) 
played an important role in BCG-induced macrophage cytotoxicity, as blockage of these 
cytokines during BCG stimulation led to substantially reduced macrophage cytotoxicity 
toward bladder cancer cells (Luo et al., 2006). In contrast, supplementation of BCG with Th1 
www.intechopen.com
 
Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
76
cytokines (e.g. rIL-2, rIL-12 or rIL-18) increased macrophage cytotoxicity by approximately 
2-fold. Consistent with these observations, rBCG strains secreting mouse IL-2 or mouse IL-
18 showed enhanced macrophage-mediated killing on bladder cancer MBT-2 cells, which 
was correlated with increased expression of IFN-γ, TNF-α and IL-6 by rBCG-stimulated 
macrophages (Luo et al., 2006). The effect of mouse IL-2 secreting rBCG strain on the 
induction of macrophage cytotoxicity toward bladder cancer MBT-2 cells was also 
demonstrated by a separate study (Yamada et al., 2000).  
3.3.2 In vivo studies 
Although the in vitro studies have suggested the potential usefulness of Th1 cytokine-
secreting rBCG strains for the treatment of bladder cancer, the effect of rBCG on treating 
bladder cancer in vivo has not well been studied. Up to date, only an rBCG strain secreting 
mouse IFN-γ (rBCG-IFN-γ) has been studied in a mouse MB49 syngeneic orthotopic tumor 
model (Arnold et al., 2004). This study showed that, with a low-dose treatment regimen, 
intravesical administration of rBCG-IFN-γ significantly prolonged animal survival 
compared to medium-treated controls, whereas BCG carrying an empty vector only slightly 
increased survival. In a similar experiment using the MB49 syngeneic orthotopic tumor 
model in IFN-γ knockout mice, intravesical treatment with rBCG-IFN-γ failed to prolong 
survival of mice, indicating that rBCG-derived IFN-γ had no measurable antitumor effect in 
the absence of endogenous IFN-γ. Studies also provided the mechanisms underlying the 
effect of rBCG-IFN-γ on treating bladder cancer. As demonstrated, this rBCG-IFN-γ strain 
could specifically upregulate the expression of MHC class I molecules on MB49 cells in vitro 
compared to control BCG, as the MHC class I upregulation could be blocked by an 
inhibitory antibody to IFN-γ. This rBCG strain also enhanced recruitment of CD4+ T cells 
into the bladder and further induced the local expression of IL-2 and IL-4 mRNA compared 
to control BCG. In addition, we have also evaluated the effects of rBCG strains secreting 
mouse IL-2 or mouse IP-10 (a Th1 chemokine) on treating bladder cancer in the MB49 
syngeneic orthotopic tumor model and observed survival benefits of these rBCG strains (our 
unpublished observations). All these observations suggest that rBCG strains secreting Th1 
cytokines or chemokines possess improved antitumor properties and may offer new 
opportunities for the treatment of bladder cancer.  
Supporting Th1 cytokine-secreting rBCG, Mycobacterium smegmatis (M. smegmatis), a closely 
related non-pathogenic mycobacterial organism, has been engineered to secrete mouse TNF-
α (M. smegmatis/TNF-α) and tested in a transplantable MB49 tumor model (Young et al., 
2004). Studies demonstrated that lymphocytes from tumor-bearing mice vaccinated with M. 
smegmatis/TNF-α produced elevated and prolonged IFN-γ but no IL-10 in response to 
mycobacterial antigen or tumor lysate stimulation in vitro. Histopathology revealed 
significantly increased infiltrating CD3+ lymphocytes in the tumor nodules of mice receiving 
the recombinant vaccine compared to those of mice receiving wild-type bacteria. These 
observations indicated that M. smegmatis/TNF-α induced cell-mediated immunity. 
Importantly, mice implanted subcutaneously with MB49 tumor and treated at an adjacent 
site with the recombinant vaccine exhibited significantly reduced tumor growth with a 70% 
durable tumor-free survival compared to those treated with wild-type bacteria or BCG (a 10-
20% long-term survival). Interestingly, treatment with M. smegmatis/TNF-α also resulted in 
similar tumor growth inhibition in T cell-deficient athymic nude mice and reduced but not 
abolished tumor growth inhibition in NK cell-deficient Beige mice. These observations 
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indicated that NK cells contribute to the antitumor effect of M. smegmatis/TNF-α but are not 
solely responsible for the eradication of tumor. Like immunocompetent mice, Beige mice 
also developed tumor specific memory after treatment with M. smegmatis/TNF-α. A study 
also demonstrated enhanced immunotherapeutic potential of a human TNF-α secreting 
recombinant M. smegmatis for treating bladder cancer (Haley et al., 1999). The ability to 
deliver immunomodulatory cytokines with no pathogenic effects makes M. smegmatis 
attractive as an alternative intravesical mycobacterial agent for bladder cancer treatment.   
4. Future perspectives 
Numerous rBCG strains secreting Th1 cytokines (e.g. IL-2, IL-18, IFN-γ and IFN-α) have 
been developed and studied. Most of them have been shown to be capable of enhancing 
BCG-induced cellular immune responses, leading to effective protection against 
mycobacterial infection in animal models. Some of them have also been shown to induce 
enhanced antitumor immunity in animal models including bladder cancer. However, up to 
date, studies on rBCG for bladder cancer treatment are limited and have not well been 
developed. Currently, a number of bladder cancer models simulating human NMIBC are 
available and have been used in anti-bladder cancer studies including BCG immunotherapy. 
These animal models provide very useful tools for the evaluation of Th1 cytokine-secreting 
rBCG strains. Since intravesical administration of IFN-γ secreting rBCG strain has been 
demonstrated to prolong survival of animals bearing bladder orthotopic tumor, other Th1 
cytokine-secreting rBCG strains are also likely effective on treating bladder cancer and 
should be evaluated in the animal models. Clinically relevant therapeutic and prophylactic 
effects of the rBCG strains relative to each other should be determined through analysis of 
the induction of antitumor responses in both effector and memory phases. The rBCG dosing 
should be optimized and the treatment schedule refined for each rBCG strain. Application 
of multiple rBCG strains for treatment should be tested and the toxic effects evaluated. 
Moreover, development of new rBCG strains will continue. We have been constructing BCG 
to secrete IL-12 (p35/p40 heterodimer) or mutant IL-10 with an intention to develop more 
potent rBCG strains for bladder cancer treatment. Furthermore, the mechanisms underlying 
rBCG actions need to be explored. In addition to classical effector cells, influence of the 
rBCG strains on Th17 and regulatory T (Treg) cells should be evaluated as the importance of 
these cell types in bladder cancer has being emerged. All these efforts will afford us a better 
understanding of Th1 cytokine-secreting rBCG strains and the steps necessary for use of 
these rBCG strains for treating bladder cancer. The pace of this research must be maintained 
if we are to improve this gold standard therapy for bladder cancer.  
5. Conclusion 
Intravesical administration of live BCG for superficial bladder cancer is the most successful 
immunotherapy for solid malignancy. However, BCG therapy is associated with significant 
toxicity and is ineffective in approximately 30-40% of cases. During the past 2 decades, the 
advances in mycobacterial genetics and molecular biology have offered unprecedented 
opportunities for the development of genetically modified BCG strains that possess 
improved safety profile, immunogenecity, and protective efficacy. Of them, manipulation of 
BCG to secrete Th1 cytokines, alone or in combination with coexpression of bacterial or 
tumor antigens, represents one of the most attractive strategies for the development of 
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improved vaccines. This type of rBCG strains has shown their potential to induce enhanced 
cellular immunity, leading to effective protection against mycobacterial infection (e.g. M.tb) 
and tumor progression (e.g. breast cancer) in various animal models. In bladder cancer 
treatment, BCG is administered intravesically; therefore, rBCG strains secreting Th1 
cytokines can augment a localized cellular immune response that is crucial for effective BCG 
immunotherapy of bladder cancer. Since intravesical BCG in combination with local 
administration of Th1 cytokines such as rIFN-α has already been used in humans and 
demonstrated to be beneficial for bladder cancer patients, Th1 cytokine-secreting rBCG 
strains could be very useful as improved BCG agents. Indeed, these rBCG strains have been 
demonstrated to be capable of inducing anti-bladder cancer immune responses both in vitro 
and in vivo in animal studies. Because of their enhanced immunogenecity, Th1 cytokine-
secreting rBCG strains can be used at a low dose, causing reduced side effects. These rBCG 
strains merit further appraisal as improved BCG immunotherapeutic agents for the 
treatment of bladder cancer.  
6. References 
Aderem, A. & Ulevitch, R.J. (2000). Toll-like receptors in the induction of the innate immune 
response. Nature, Vol. 406, No. 6797, (August 2000), pp. 782-787, PMID: 10963608. 
Aldovini, A. & Young, R.A. (1991). Humoral and cell-mediated immune responses to live 
recombinant BCG-HIV vaccines. Nature, Vol. 351, No. 6326, (June 1991), pp. 479-
482, PMID: 2046750. 
Alexandroff, A.B.; Nicholson, S.; Patel, P.M. & Jackson, A.M. (2010). Recent advances in 
bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy, Vol. 2, 
No. 4, (July 2010), pp. 551-560, PMID: 20636008. 
Andrade, P.M.; Chade, D.C.; Borra, R.C.; Nascimento, I.P.; Villanova, F.E.; Leite, L.C.; 
Andrade, E. & Srougi, M. (2010). The therapeutic potential of recombinant BCG 
expressing the antigen S1PT in the intravesical treatment of bladder cancer. Urol. 
Oncol., Vol. 28, No. 5, (September 2010 ), pp. 520-525, PMID: 19272796. 
Arnold, J.; de Boer, E.C.; O'Donnell, M.A.; Böhle, A. & Brandau, S. (2004). Immunotherapy of 
experimental bladder cancer with recombinant BCG expressing interferon-gamma. 
J. Immunother., Vol. 27, No. 2, (March 2004), pp. 116-123, PMID: 14770083. 
Babjuk, M.; Oosterlinck, W.; Sylvester, R.; Kaasinen, E.; Böhle, A. & Palou-Redorta, J; 
European Association of Urology (EAU). (2008). EAU guidelines on non-muscle-
invasive urothelial carcinoma of the bladder. Eur. Urol., Vol. 54, No. 2, (August 
2008), pp. 303-314, PMID: 18468779. 
Bastos, R.G.; Borsuk, S.; Seixas, F.K. & Dellagostin, O.A. (2009). Recombinant 
Mycobacterium bovis BCG. Vaccine, Vol. 27, No. 47, (November 2009), pp. 6495-
6503, PMID: 19720367. 
Bazarbashi, S.; Soudy, H.; Abdelsalam, M.; Al-Jubran, A.; Akhtar, S.; Memon, M.; Aslam, M.; 
Kattan, S. & Shoukri, M. (2011). Co-administration of intravesical bacillus Calmette-
Guérin and interferon α-2B as first line in treating superficial transitional cell 
carcinoma of the urinary bladder. BJU. Int., (February 2011), [Epub ahead of print], 
PMID: 21332904. 
Becich, M.J.; Carroll, S. & Ratliff, T.L. (1991). Internalization of bacille Calmette-Guerin by 
bladder tumor cells. J. Urol., Vol. 145, No. 6, (June 1991), pp. 1316-1324, PMID: 
2033723. 
www.intechopen.com
Th1 Cytokine-Secreting Recombinant Bacillus Calmette-Guérin:  
Prospective Use in Immunotherapy of Bladder Cancer 
 
79 
Bevers, R.F.; Kurth, K.H. & Schamhart, D.H. (2004). Role of urothelial cells in BCG 
immunotherapy for superficial bladder cancer. Br. J. Cancer, Vol. 91, No. 4, (August 
2004), pp. 607-612, PMID: 15266312. 
Biet, F.; Kremer, L.; Wolowczuk, I.; Delacre, M. & Locht, C. (2002). Mycobacterium bovis 
BCG producing interleukin-18 increases antigen-specific gamma interferon 
production in mice. Infect. Immun., Vol. 70, No. 12, (December 2002), pp. 6549-6557, 
PMID: 12438324. 
Biet, F.; Kremer, L.; Wolowczuk, I.; Delacre, M. & Locht, C. (2003). Immune response 
induced by recombinant Mycobacterium bovis BCG producing the cholera toxin B 
subunit. Infect. Immun., Vol. 71, No. 5, (May 2003), pp. 2933-2937, PMID: 12704173. 
Biet, F.; Duez, C.; Kremer, L.; Marquillies, P.; Amniai, L.; Tonnel, A.B.; Locht, C. & Pestel, J. 
(2005). Recombinant Mycobacterium bovis BCG producing IL-18 reduces IL-5 
production and bronchoalveolar eosinophilia induced by an allergic reaction. 
Allergy, Vol. 60, No. 8, (August 2005), pp. 1065-1072, PMID:15969689. 
Bilen, C.Y.; Inci, K.; Erkan, I. & Ozen, H. (2003). The predictive value of purified protein 
derivative results on complications and prognosis in patients with bladder cancer 
treated with bacillus Calmette-Guerin. J. Urol., Vol. 169, No. 5, (May 2003), pp. 
1702-1705, PMID: 12686812. 
aBöhle, A.; Gerdes, J.; Ulmer, A.J.; Hofstetter, A.G. & Flad, H.D. (1990). Effects of local 
bacillus Calmette-Guerin therapy in patients with bladder carcinoma on 
immunocompetent cells of the bladder wall. J. Urol., Vol. 144, No. 1, (July 1990), pp. 
53-58, PMID: 2359181. 
bBöhle, A.; Nowc, C.; Ulmer, A.J.; Musehold, J.; Gerdes, J.; Hofstetter, A.G. & Flad, H.D. 
(1990). Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis 
factor in the urine of patients after intravesical bacillus Calmette-Guerin 
immunotherapy. J. Urol., Vol. 144, No. 1, (July 1990), pp. 59-64, PMID: 2193171. 
Böhle, A.; Thanhäuser, A,; Ulmer, A.J.; Ernst, M.; Flad, H.D. & Jocham, D. (1993). Dissecting 
the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence 
of a distinct BCG-activated killer (BAK) cell phenomenon. J. Urol., Vol. 150, No. 6, 
(December 1993), pp. 1932-1937, PMID: 8230540. 
aBrandau, S.; Böhle, A.; Thanhäuser, A.; Ernst, M.; Mattern, T.; Ulmer, A.J. & Flad, H.D. 
(2000). In vitro generation of bacillus Calmette-Guérin-activated killer cells. Clin. 
Infect. Dis., Vol. 31, No. Suppl 3, (September 2000), pp. S94-S100, PMID: 11010832. 
bBrandau, S,; Suttmann, H.; Riemensberger, J.; Seitzer, U.; Arnold, J.; Durek, C.; Jocham, D.; 
Flad, H.D. & Böhle, A. (2000). Perforin-mediated lysis of tumor cells by 
Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells. Clin. Cancer 
Res., Vol. 6, No. 9, (September 2000), pp. 3729-3738, PMID: 10999767. 
Brandau, S.; Riemensberger, J.; Jacobsen, M.; Kemp, D.; Zhao, W.; Zhao, X.; Jocham, D.; 
Ratliff, T.L. & Böhle, A. (2001). NK cells are essential for effective BCG 
immunotherapy. Int. J. Cancer, Vol. 92, No. 5, (June 2001), pp. 697-702, PMID: 
11340575. 
Brandau, S. & Suttmann, H. (2007). Thirty years of BCG immunotherapy for non-muscle 
invasive bladder cancer: a success story with room for improvement. Biomed. 
Pharmacother., Vol. 61, No. 6, (July 2007), pp. 299-305, PMID: 17604943. 
Chade, D.C.; Borra, R.C.; Nascimento, I.P.; Villanova, F.E.; Leite, L.C.; Andrade, E.; Srougi, 
M.; Ramos, K.L. & Andrade, P.M. (2008). Immunomodulatory effects of 
www.intechopen.com
 
Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
80
recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder 
cancer model. J. Exp. Clin. Cancer Res., Vol. 27, (November 2008), pp. 78, PMID: 
19040745. 
Chen, F.H.; Crist, S.A.; Zhang, G.J.; Iwamoto, Y. & See, W.A. (2002). Interleukin-6 
production by human bladder tumor cell lines is up-regulated by bacillus Calmette-
Guérin through nuclear factor-kappaB and Ap-1 via an immediate early pathway. J. 
Urol., Vol. 168, No. 2, (August 2002), pp. 786-797, PMID: 12131369. 
Chen, F.; Zhang, G.; Iwamoto, Y. & See, W.A. (2005). BCG directly induces cell cycle arrest in 
human transitional carcinoma cell lines as a consequence of integrin cross-linking. 
BMC Urol., Vol. 12, No. 5, (May 2005), pp. 8, PMID: 15890073. 
Chen, X.; O'Donnell, M.A. & Luo, Y. (2007). Dose-dependent synergy of Th1-stimulating 
cytokines on bacille Calmette-Guérin-induced interferon-gamma production by 
human mononuclear cells. Clin. Exp. Immunol., Vol. 149, No. 1, (July 2007), pp. 178-
185, PMID: 17517055. 
Chung, M.A.; Luo, Y.; O'Donnell, M.; Rodriguez, C.; Heber, W.; Sharma, S. & Chang, H.R. 
(2003). Development and preclinical evaluation of a Bacillus Calmette-Guérin-
MUC1-based novel breast cancer vaccine. Cancer Res., Vol. 63, No. 6, (March 2003), 
pp. 1280-1287, PMID: 12649188. 
Connell, N.D.; Medina-Acosta, E.; McMaster, W.R.; Bloom, B.R. & Russell, D.G. (1993). 
Effective immunization against cutaneous leishmaniasis with recombinant bacille 
Clamette-Guérin expressing the Leishmania surface proteinase gp63. Proc. Natl. 
Acad. Sci. USA, Vol. 90, No. 24, (December 1993), pp. 11473-11477, PMID: 8265576. 
aDe Boer, E.C.; de Jong, W.H.; van der Meijden, A.P.; Steerenberg, P.A.; Witjes, F.; Vegt, P.D.; 
Debruyne, F.M. & Ruitenberg, E.J. (1991). Leukocytes in the urine after intravesical 
BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. 
Urol. Res., Vol. 19, No. 1, (1991), pp. 45-50, PMID: 2028562. 
bDe Boer, E.C.; de Jong, W.H.; van der Meijden, A.P.; Steerenberg, P.A.; Witjes, J.A.; Vegt, 
P.D.; Debruyne, F.M. & Ruitenberg, E.J. (1991). Presence of activated lymphocytes 
in the urine of patients with superficial bladder cancer after intravesical 
immunotherapy with bacillus Calmette-Guérin. Cancer Immunol. Immunother., Vol. 
33, No. 6, (1991), pp. 411-416, PMID: 1878894. 
cDe Boer, E.C.; De Jong, W.H.; Steerenberg, P.A.; Van der Meijden, A.P.; Aarden, L.A.; 
Debruyne, F.M. & Ruitenberg, E.J. (1991). Leukocytes and cytokines in the urine of 
superficial bladder cancer patients after intravesical immunotherapy with bacillus 
Calmette-Guerin. In Vivo. Vol. 5, No. 6, (November 1991), pp. 671-677, PMID: 
1810454. 
Den Otter, W.; Dobrowolski, Z.; Bugajski, A.; Papla, B.; Van Der Meijden, A.P.; Koten, J.W.; 
Boon, T.A.; Siedlar, M. & Zembala, M. (1998). Intravesical interleukin-2 in T1 
papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J. Urol., 
Vol. 159, No. 4, (April 1998), pp. 1183-1186, PMID: 9507828. 
De Reijke, T.M.; De Boer, E.C.; Kurth, K.H. & Schamhart, D.H. (1996). Urinary cytokines 
during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: 
processing, stability and prognostic value. J. Urol., Vol. 155, No. 2, February 1996), 
pp. 477-482, PMID: 8558640. 
www.intechopen.com
Th1 Cytokine-Secreting Recombinant Bacillus Calmette-Guérin:  
Prospective Use in Immunotherapy of Bladder Cancer 
 
81 
Duda, R.B.; Yang, H.; Dooley, D.D. & Abu-Jawdeh, G. (1995). Recombinant BCG therapy 
suppresses melanoma tumor growth. Ann. Surg. Oncol., Vol. 3, No. 6, (November 
1995), pp. 542-549, PMID: 8591086. 
Elzey, B.D.; Siemens, D.R.; Ratliff, T.L. & Lubaroff, D.M. (2001). Immunization with type 5 
adenovirus recombinant for a tumor antigen in combination with recombinant 
canarypox virus (ALVAC) cytokine gene delivery induces destruction of 
established prostate tumors. Int. J. Cancer, Vol. 94, No. 6, (December 2001), pp. 842-
849, PMID: 11745487. 
Emoto, M.; Emoto, Y.; Buchwalow, I.B. & Kaufmann, S.H. (1999). Induction of IFN-gamma-
producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette 
Guérin. Eur. J. Immunol., Vol. 29, No. 2, (February 1999), pp. 650-659, PMID: 
10064082. 
Fan, X.L.; Yu, T.H.; Gao, Q. & Yao, W. (2006). Immunological properties of recombinant 
Mycobacterium bovis bacillus Calmette-Guérin strain expressing fusion protein IL-
2-ESAT-6. Acta. Biochim. Biophys. Sin (Shanghai), Vol. 38, No. 10, (October 2006), pp. 
683-690, PMID: 17033714. 
Ferlazzo, G.; Magno, C.; Iemmo, R.; Rizzo, M.; Lupo, G.; Semino, C.; Bruno, S. & Melioli, G. 
(1996). Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: 
a follow-up study. Anticancer Res., Vol. 16, No. 2, (March 1996), pp. 979-980, PMID: 
8687163. 
Flynn, J.L. & Chan, J. (2001). Immunology of tuberculosis. Annu. Rev. Immunol., Vol. 19, 
(2001), pp. 93-129, PMID: 11244032. 
Geliebter, J. (2010). Immunotherapy for prostate cancer using recombinant bacille Calmette-
Guerin expressing prostate specific antigens. United States Patent Application 
20100316668, (December 2010).  
Giannopoulos, A.; Constantinides, C.; Fokaeas, E.; Stravodimos, C.; Giannopoulou, M.; 
Kyroudi, A. & Gounaris, A. (2003). The immunomodulating effect of interferon-
gamma intravesical instillations in preventing bladder cancer recurrence. Clin. 
Cancer Res., Vol. 9, No. 15, (November 2003), pp. 5550-5558, PMID: 14654535. 
Godaly, G. & Young, D.B. (2005). Mycobacterium bovis bacille Calmette Guerin infection of 
human neutrophils induces CXCL8 secretion by MyD88-dependent TLR2 and 
TLR4 activation. Cell Microbiol., Vol. 7, No. 4, (April 2005), pp. 591-601, PMID: 
15760459. 
Grode, L.; Kursar, M.; Fensterle, J.; Kaufmann, S.H. & Hess, J. (2002). Cell-mediated 
immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guérin 
strains against an intracellular bacterial pathogen: importance of antigen secretion 
or membrane-targeted antigen display as lipoprotein for vaccine efficacy. J. 
Immunol., Vol. 168, No. 4, (February 2002), pp. 1869-1876, PMID: 11823521. 
Haley, J.L.; Young, D.G.; Alexandroff, A.; James, K. & Jackson, A.M. (1999). Enhancing the 
immunotherapeutic potential of mycobacteria by transfection with tumour necrosis 
factor-alpha. Immunology, Vol. 96, No. 1, (January 1999), pp. 114-121, PMID: 
10233685. 
Hall, M.C.; Chang, S.S.; Dalbagni, G.; Pruthi, R.S.; Seigne, J.D.; Skinner, E.C.; Wolf, J.S. Jr. & 
Schellhammer, P.F. (2007). Guideline for the management of nonmuscle invasive 
bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol., Vol. 178, No. 6, 
(December 2007), pp. 2314-2330, PMID: 17993339. 
www.intechopen.com
 
Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
82
He, J.; Shen, D.; O'Donnell, M.A. & Chang, H.R. (2002). Induction of MUC1-specific cellular 
immunity by a recombinant BCG expressing human MUC1 and secreting IL2. Int. J. 
Oncol., Vol. 20, No. 6, (June 2002), pp. 1305-1311, PMID: 12012014. 
Heldwein, K.A.; Liang, M.D.; Andresen, T.K.; Thomas, K.E.; Marty, A.M.; Cuesta, N.; Vogel, 
S.N. & Fenton, M.J. (2003). TLR2 and TLR4 serve distinct roles in the host immune 
response against Mycobacterium bovis BCG. J. Leukoc. Biol., Vol. 74, No. 2, (August 
2003), pp. 277-286, PMID: 12885945. 
Higuchi, T.; Shimizu, M.; Owaki, A.; Takahashi, M.; Shinya, E.; Nishimura, T. & Takahashi, 
H. (2009). A possible mechanism of intravesical BCG therapy for human bladder 
carcinoma: involvement of innate effector cells for the inhibition of tumor growth. 
Cancer Immunol. Immunother., Vol. 58, No. 8, (August 2009), pp. 1245-1255, PMID: 
19139883. 
Honda, M.; Matsuo, K.; Nakasone, T.; Okamoto, Y.; Yoshizaki, H.; Kitamura, K.; Sugiura, 
W.; Watanabe, K.; Fukushima, Y.; Haga, S.; Katsura, Y.; Tasaka, H.; Komuro, K.; 
Yamada, T.; Asano, T.; Yamazaki, A. & Yamazaki, S. (1995). Protective immune 
responses induced by secretion of a chimeric soluble protein from a recombinant 
Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human 
immunodeficiency virus type 1 in small animals. Proc. Natl. Acad. Sci. USA, Vol. 92, 
No. 23, (November 1995), pp. 10693-10697, PMID: 7479867. 
Horwitz, M.A.; Harth, G.; Dillon, B.J. & Maslesa-Galic', S. (2000). Recombinant bacillus 
calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa 
major secretory protein induce greater protective immunity against tuberculosis 
than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. 
Acad. Sci. USA, Vol. 97, No. 25, (December 2000), pp. 13853-13858, PMID: 11095745. 
Hulseberg, P.D.; Zozulya, A.; Chu, H.H.; Triccas, J.A.; Fabry, Z. & Sandor, M. (2010). The 
same well-characterized T cell epitope SIINFEKL expressed in the context of a 
cytoplasmic or secreted protein in BCG induces different CD8+ T cell responses. 
Immunol. Lett., Vol. 130, No. 1-2, (May 2010), pp. 36-42, PMID: 20005257. 
Ikeda, N.; Toida, I.; Iwasaki, A.; Kawai, K. & Akaza, H. (2002). Surface antigen expression on 
bladder tumor cells induced by bacillus Calmette-Guérin (BCG): A role of BCG 
internalization into tumor cells. Int. J. Urol., Vol. 9, No. 1, (January 2002), pp. 29-35, 
PMID: 11972647. 
Jackson, A.M.; Hawkyard, S.J.; Prescott, S.; Ritchie, A.W.; James, K. & Chisholm, G.D. (1992). 
An investigation of factors influencing the in vitro induction of LAK activity 
against a variety of human bladder cancer cell lines. J. Urol., Vol. 147, No. 1, 
(January 1992), pp. 207-211, PMID: 1729534. 
Jacobs, W.R. Jr; Tuckman, M. & Bloom, B.R. (1987). Introduction of foreign DNA into 
mycobacteria using a shuttle phasmid. Nature, Vol. 327, No. 6122, (June 1987), pp. 
532-535, PMID: 3473289. 
Jansson, O.T.; Morcos, E.; Brundin, L.; Lundberg, J.O.; Adolfsson, J.; Söderhäll, M. & 
Wiklund, N.P. (1998). The role of nitric oxide in bacillus Calmette-Guérin mediated 
anti-tumour effects in human bladder cancer. Br. J. Cancer, Vol. 78, No. 5, 
(September 1998), pp. 588-592, PMID: 9744496. 
Jemal, A.; Siegel, R.; Xu, J. & Ward, E. (2010). Cancer statistics. CA. Cancer J. Clin., Vol. 60, 
No. 5, (September 2010), pp. 277-300, PMID: 20610543. 
www.intechopen.com
Th1 Cytokine-Secreting Recombinant Bacillus Calmette-Guérin:  
Prospective Use in Immunotherapy of Bladder Cancer 
 
83 
Joudi, F.N.; Smith, B.J. & O'Donnell, M.A. National BCG-Interferon Phase 2 Investigator 
Group. (2006). Final results from a national multicenter phase II trial of 
combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing 
recurrence of superficial bladder cancer. Urol. Oncol., Vol. 24, No. 4, (July 2006), pp. 
344-348, PMID: 16818189. 
Kavoussi, L.R.; Brown, E.J.; Ritchey, J.K. & Ratliff, T.L. (1990). Fibronectin-mediated 
Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for 
the expression of an antitumor response. J. Clin. Invest., Vol. 85, No. 1, (January 
1990), pp. 62-67, PMID: 2404029. 
Kawashima, T.; Norose, Y.; Watanabe, Y.; Enomoto, Y.; Narazaki, H.; Watari, E.; Tanaka, S.; 
Takahashi, H.; Yano, I.; Brenner, M.B. & Sugita, M. (2003). Cutting edge: major CD8 
T cell response to live bacillus Calmette-Guérin is mediated by CD1 molecules. J. 
Immunol., Vol. 170, No. 11, (June 2003), pp. 5345-5348, PMID: 12759406. 
Kemp, T.J; Ludwig, A.T.; Earel, J.K.; Moore, J.M.; Vanoosten, R.L.; Moses, B.; Leidal, K.; 
Nauseef, W.M. & Griffith, T.S. (2005). Neutrophil stimulation with Mycobacterium 
bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble 
TRAIL/Apo-2L. Blood, Vol. 106, No. 10, (November 2005), pp. 3474-3482, PMID: 
16037389. 
Kong, D. & Kunimoto, D.Y. (1995). Secretion of human interleukin 2 by recombinant 
Mycobacterium bovis BCG. Infect. Immun., Vol. 63, No. 3, (March 1995), pp. 799-803, 
PMID: 7868249. 
Lam, J.S.; Benson, M.C.; O'Donnell, M.A.; Sawczuk, A.; Gavazzi, A.; Wechsler, M.H. & 
Sawczuk, I.S. (2003). Bacillus Calmete-Guérin plus interferon-alpha2B intravesical 
therapy maintains an extended treatment plan for superficial bladder cancer with 
minimal toxicity. Urol. Oncol., Vol. 21, No. 5, (September 2003), pp. 354-360, PMID: 
14670544. 
Lamm, D.L.; Blumenstein, B.A.; Crissman, J.D.; Montie, J.E.; Gottesman, J.E.; Lowe, B.A.; 
Sarosdy, M.F.; Bohl, R.D.; Grossman, H.B.; Beck, T.M.; Leimert, J.T. & Crawford, 
E.D. (2000). Maintenance bacillus Calmette-Guerin immunotherapy for recurrent 
TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a 
randomized Southwest Oncology Group Study. J. Urol., Vol. 163, No. 4, (April 
2000), pp. 1124-1129, PMID: 10737480. 
aLangermann, S.; Palaszynski, S.R.; Burlein, J.E.; Koenig, S.; Hanson, M.S.; Briles, D.E. & 
Stover, C.K. (1994). Protective humoral response against pneumococcal infection in 
mice elicited by recombinant bacille Calmette-Guérin vaccines expressing 
pneumococcal surface protein A. J. Exp. Med., Vol. 180, No. 6, (December 1994), pp. 
2277-2286, PMID: 7964500. 
bLangermann, S.; Palaszynski, S.; Sadziene, A.; Stover, C.K. & Koenig, S. (1994). Systemic 
and mucosal immunity induced by BCG vector expressing outer-surface protein A 
of Borrelia burgdorferi. Nature, Vol. 372, No. 6506, (December 1994), pp. 552-555, 
PMID: 7990928. 
Lee, M.H.; Pascopella. L.; Jacobs, W.R. Jr. & Hatfull, G.F. (1991). Site-specific integration of 
mycobacteriophage L5: integration-proficient vectors for Mycobacterium 
smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guérin. Proc. Natl. 
Acad. Sci. USA, Vol. 88, No. 8, (April 1991), pp. 3111-3115, PMID: 1901654. 
www.intechopen.com
 
Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
84
Liu, W.; O'Donnell, M.A.; Chen, X.; Han, R. & Luo, Y. (2009). Recombinant bacillus 
Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human 
mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer 
Immunol. Immunother., Vol. 58, No. 10, (October 2009), pp. 1647-1655, PMID: 
19214503. 
Lodillinsky, C.; Umerez, M.S.; Jasnis, M.A.; Casabé, A.; Sandes, E. & Eiján, A.M. (2006). 
Bacillus Calmette-Guérin induces the expression of peroxisome proliferator-
activated receptor gamma in bladder cancer cells. Int. J. Mol. Med., Vol. 17, No. 2, 
(February 2006), pp. 269-273, PMID: 16391825. 
Ludwig, A.T.; Moore, J.M.; Luo, Y.; Chen, X.; Saltsgaver, N.A.; O'Donnell, M.A. & Griffith, 
T.S. (2004). Tumor necrosis factor-related apoptosis-inducing ligand: a novel 
mechanism for Bacillus Calmette-Guérin-induced antitumor activity. Cancer Res., 
Vol. 64, No. 10, (May 2004), pp. 3386-3390, PMID: 15150089. 
Luo, Y.; Szilvasi, A.; Chen, X.; DeWolf, W.C. & O'Donnell, M.A. (1996). A novel method for 
monitoring Mycobacterium bovis BCG trafficking with recombinant BCG 
expressing green fluorescent protein. Clin. Diagn. Lab. Immunol., Vol. 3, No. 6, 
(November 1996), pp. 761-768, PMID: 8914772. 
Luo, Y.; Chen, X.; Downs, T.M.; DeWolf, W.C. & O'Donnell, M.A. (1999). IFN-alpha 2B 
enhances Th1 cytokine responses in bladder cancer patients receiving 
Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J. Immunol., Vol. 
162, No. 4, (February 1999), pp. 2399-2405, PMID: 9973521. 
Luo, Y.; Chen, X.; Szilvasi, A. & O'Donnell, M.A. (2000). Co-expression of interleukin-2 and 
green fluorescent protein reporter in mycobacteria: in vivo application for 
monitoring antimycobacterial immunity. Mol. Immunol., Vol. 37, No. 9, (June 2000), 
pp. 527-536, PMID: 11163402. 
Luo, Y.; Chen, X.; Han, R. & O'Donnell, M.A. (2001). Recombinant bacille Calmette-Guérin 
(BCG) expressing human interferon-alpha 2B demonstrates enhanced 
immunogenicity. Clin. Exp. Immunol., Vol. 123, No. 2, (February 2001), pp. 264-270, 
PMID: 11207657. 
Luo, Y.; Chen, X. & O'Donnell, M.A. (2003). Role of Th1 and Th2 cytokines in BCG-induced 
IFN-gamma production: cytokine promotion and simulation of BCG effect. 
Cytokine, Vol. 21, No. 1, (January 2003), pp. 17-26, PMID: 12668155. 
Luo, Y.; Yamada, H.; Chen, X.; Ryan, A.A.; Evanoff, D.P.; Triccas, J.A. & O'Donnell, M.A. 
(2004). Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) 
expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. 
Clin. Exp. Immunol., Vol. 137, No. 1, (July 2004), pp. 24-34, PMID: 15196240. 
Luo, Y.; Yamada, H.; Evanoff, D.P. & Chen, X. (2006). Role of Th1-stimulating cytokines in 
bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse 
bladder cancer MBT-2 cells. Clin. Exp. Immunol., Vol. 146, No. 1, (October 2006), pp. 
181-188, PMID: 16968412. 
Luo, Y.; Chen, X. & O'Donnell, M.A. (2007). Mycobacterium bovis bacillus Calmette-Guérin 
(BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin. Exp. 
Immunol., Vol. 147, No. 2, (February 2007), pp. 370-378, PMID: 17223980. 
Luo, Y.; Han, R.; Evanoff, D.P. & Chen, X. (2010). Interleukin-10 inhibits Mycobacterium 
bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against 
www.intechopen.com
Th1 Cytokine-Secreting Recombinant Bacillus Calmette-Guérin:  
Prospective Use in Immunotherapy of Bladder Cancer 
 
85 
bladder cancer cells. Clin. Exp. Immunol., Vol. 160, No. 3, (June 2010), pp. 359-368, 
PMID: 20148913. 
Mansure, J.J.; Nassim, R. & Kassouf, W. (2009). Peroxisome proliferator-activated receptor 
gamma in bladder cancer: a promising therapeutic target. Cancer Biol. Ther., Vol. 8, 
No. 7, (April 2009), pp. 6-15, PMID: 19417560. 
Matsuo, K.; Yamaguchi, R.; Yamazaki, A.; Tasaka, H.; Terasaka, K.; Totsuka, M.; Kobayashi, 
K.; Yukitake, H. & Yamada, T. (1990). Establishment of a foreign antigen secretion 
system in mycobacteria. Infect. Immun., Vol. 58, No. 12, (December 1990), pp. 4049-
4054, PMID: 1701418. 
Mittrücker, H.W.; Steinhoff, U.; Köhler, A.; Krause, M.; Lazar, D.; Mex, P.; Miekley, D. & 
Kaufmann, S.H. (2007). Poor correlation between BCG vaccination-induced T cell 
responses and protection against tuberculosis. Proc. Natl. Acad. Sci. USA, Vol. 104, 
No. 30, (July 2007), pp. 12434-12439, PMID: 17640915. 
Morales, A.; Eidinger, D. & Bruce, A.W. (1976). Intracavitary Bacillus Calmette-Guerin in the 
treatment of superficial bladder tumors. J. Urol., Vol. 116, No. 2, (August 1976), pp. 
180-183, PMID: 820877. 
Moreira, A.L.; Tsenova, L.; Murray, P.J.; Freeman, S.; Bergtold, A.; Chiriboga, L. & Kaplan, 
G. (2000). Aerosol infection of mice with recombinant BCG secreting murine IFN-
gamma partially reconstitutes local protective immunity. Microb. Pathog., Vol. 29, 
No. 3, (September 2000), pp. 175-185, PMID: 10968949. 
Murray, A.; Winter, N.; Lagranderie, M.; Hill, D.F.; Rauzier, J.; Timm, J.; Leclerc, C.; 
Moriarty, K.M.; Gheorghiu, M. & Gicquel, B. (1992). Expression of Escherichia coli 
beta-galactosidase in Mycobacterium bovis BCG using an expression system 
isolated from Mycobacterium paratuberculosis which induced humoral and 
cellular immune responses. Mol. Microbiol., Vol. 6, No. 22, (November 1992), pp. 
3331-3342, PMID: 1336563. 
Murray, P.J.; Aldovini, A. & Young, R.A. (1996). Manipulation and potentiation of 
antimycobacterial immunity using recombinant bacille Calmette-Guérin strains 
that secrete cytokines. Proc. Natl. Acad. Sci. USA, Vol. 93, No. 2, (January 1996), pp. 
934-939, PMID: 8570663. 
Mylona, E.; Giannopoulou, I.; Diamantopoulou, K.; Bakarakos, P.; Nomikos, A.; Zervas, A. 
& Nakopoulou, L. (2009). Peroxisome proliferator-activated receptor gamma 
expression in urothelial carcinomas of the bladder: association with differentiation, 
proliferation and clinical outcome. Eur. J. Surg. Oncol., Vol. 35, No. 2, (February 
2009), pp. 197-201, PMID: 18513919. 
Nadler, R.; Luo, Y.; Zhao, W.; Ritchey, J.K.; Austin, J.C.; Cohen, M.B.; O'Donnell, M.A. & 
Ratliff, T.L. (2003). Interleukin 10 induced augmentation of delayed-type 
hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin 
(BCG) mediated antitumour activity. Clin. Exp. Immunol., Vol. 131, No. 2, (February 
2003), pp. 206-216, PMID: 12562379. 
Nepple, K.G.; Lightfoot, A.J.; Rosevear, H.M.; O'Donnell, M.A. & Lamm, D.L.; Bladder 
Cancer Genitourinary Oncology Study Group. (2010). Bacillus Calmette-Guérin 
with or without interferon α-2b and megadose versus recommended daily 
allowance vitamins during induction and maintenance intravesical treatment of 
nonmuscle invasive bladder cancer. J. Urol., Vol. 184, No. 5, (November 2010), pp. 
1915-1919, PMID: 20846688. 
www.intechopen.com
 
Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
86
O'Donnell, M.A.; Aldovini, A.; Duda, R.B.; Yang, H.; Szilvasi, A.; Young, R.A. & DeWolf, 
W.C. (1994). Recombinant Mycobacterium bovis BCG secreting functional 
interleukin-2 enhances gamma interferon production by splenocytes. Infect. Immun., 
Vol. 62, No. 6, (June 1994), pp. 2508-2514, PMID: 8188376. 
O'Donnell, M.A.; Luo, Y.; Chen, X.; Szilvasi, A.; Hunter, S.E. & Clinton, S.K. (1999). Role of 
IL-12 in the induction and potentiation of IFN-gamma in response to bacillus 
Calmette-Guérin. J. Immunol., Vol. 163, No. 8, (October 1999), pp. 4246-4252, PMID: 
10510362. 
O'Donnell, M.A.; Krohn, J. & DeWolf, W.C. (2001). Salvage intravesical therapy with 
interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients 
with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously 
failed. J. Urol., Vol. 166, No. 4, (October 2001), pp. 1300-1304, PMID: 11547062. 
Ping, S.Y.; Wu, C.L. & Yu, D.S. (2010). Sunitinib can enhance BCG mediated cytotoxicity to 
transitional cell carcinoma through apoptosis pathway. Urol. Oncol., (September 
2010), [Epub ahead of print], PMID: 20884251. 
Pook, S.H.; Rahmat, J.N.; Esuvaranathan, K. & Mahendran, R. (2007). Internalization of 
Mycobacterium bovis, Bacillus Calmette Guerin, by bladder cancer cells is 
cytotoxic. Oncol. Rep., Vol. 18, No. 5, (November 2007), pp. 1315-1320, PMID: 
17914591. 
Prescott, S.; James, K.; Hargreave, T.B.; Chisholm, G.D. & Smyth, J.F. (1992). Intravesical 
Evans strain BCG therapy: quantitative immunohistochemical analysis of the 
immune response within the bladder wall. J. Urol., Vol. 147, No. 6, (June 1992), pp. 
1636-1642, PMID: 1593713. 
Pryor, K.; Goddard, J.; Goldstein, D.; Stricker, P.; Russell, P.; Golovsky, D. & Penny, R. 
(1995). Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-
mediated bladder tumour cell killing. Br. J. Cancer, Vol. 71, No. 4, (April 1995), pp. 
801-807, PMID: 7710947. 
Pym, A.S.; Brodin, P.; Majlessi, L.; Brosch, R.; Demangel, C.; Williams, A.; Griffiths, K.E.; 
Marchal, G.; Leclerc, C. & Cole, S.T. (2003). Recombinant BCG exporting ESAT-6 
confers enhanced protection against tuberculosis. Nat. Med., Vol. 9, No. 5, (May 
2003), pp. 533-539, PMID: 12692540. 
Ratliff, T.L.; Ritchey, J.K.; Yuan, J.J.; Andriole, G.L. & Catalona, W.J. (1993). T-cell subsets 
required for intravesical BCG immunotherapy for bladder cancer. J. Urol., Vol. 150, 
No. 3, (September 1993), pp. 1018-1023, PMID: 8102183. 
Reale, M.; Intorno, R.; Tenaglia, R.; Feliciani, C.; Barbacane, R.C.; Santoni, A. & Conti, P. 
(2002). Production of MCP-1 and RANTES in bladder cancer patients after bacillus 
Calmette-Guerin immunotherapy. Cancer Immunol. Immunother., Vol. 51, No. 2, 
(April 2002), pp. 91-98, PMID: 11904733. 
Riemensberger, J.; Böhle, A. & Brandau, S. (2002). IFN-gamma and IL-12 but not IL-10 are 
required for local tumour surveillance in a syngeneic model of orthotopic bladder 
cancer. Clin. Exp. Immunol., Vol. 127, No. 1, (January 2002), pp. 20-26, PMID: 
11882028. 
aRyan, A.A.; Wozniak, T.M.; Shklovskaya, E.; O'Donnell, M.A.; Fazekas de St Groth, B.; 
Britton, W.J. & Triccas, J.A. (2007). Improved protection against disseminated 
tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine 
www.intechopen.com
Th1 Cytokine-Secreting Recombinant Bacillus Calmette-Guérin:  
Prospective Use in Immunotherapy of Bladder Cancer 
 
87 
GM-CSF is associated with expansion and activation of APCs. J. Immunol., Vol. 179, 
No. 12, (December 2007), pp. 8418-8424, PMID: 18056388. 
bRyan, A.A.; Spratt, J.M.; Britton, W.J. & Triccas, J.A. (2007). Secretion of functional 
monocyte chemotactic protein 3 by recombinant Mycobacterium bovis BCG 
attenuates vaccine virulence and maintains protective efficacy against M. 
tuberculosis infection. Infect. Immun., Vol. 75, No. 1, (January 2007), pp. 523-526, 
PMID: 17074853. 
aSaban, M.R.; Simpson, C.; Davis, C.; Wallis, G.; Knowlton, N.; Frank, M.B.; Centola, M.; 
Gallucci, R.M. & Saban, R. (2007). Discriminators of mouse bladder response to 
intravesical Bacillus Calmette-Guerin (BCG). BMC Immunol., Vol. 8, (May 2007), pp. 
6, PMID: 17506885. 
bSaban, M.R.; Hellmich, H.L.; Simpson, C.; Davis, C.A.; Lang, M.L.; Ihnat, M.A.; O'Donnell, 
M.A.; Wu, X.R. & Saban, R. (2007). Repeated BCG treatment of mouse bladder 
selectively stimulates small GTPases and HLA antigens and inhibits single-
spanning uroplakins. BMC Cancer, Vol. 7, (November 2007), pp. 204, PMID: 
17980030. 
Saint, F.; Patard, J.J.; Maille, P.; Soyeux, P.; Hoznek, A.; Salomon, L.; Abbou, C.C. & Chopin, 
D.K. (2002). Prognostic value of a T helper 1 urinary cytokine response after 
intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J. 
Urol., Vol. 167, No. 1, (January 2002), pp. 364-367, PMID: 11743357. 
See, W.A.; Zhang, G.; Chen, F.; Cao, Y.; Langenstroer, P. & Sandlow, J. (2009). Bacille-
Calmette Guèrin induces caspase-independent cell death in urothelial carcinoma 
cells together with release of the necrosis-associated chemokine high molecular 
group box protein 1. BJU. Int., Vol. 103, No. 12, (June 2009), pp. 1714-1720, PMID: 
19154459. 
See, W.A.; Zhang, G.; Chen, F. & Cao, Y. (2010). p21 Expression by human urothelial 
carcinoma cells modulates the phenotypic response to BCG. Urol. Oncol., Vol. 28, 
No. 5, (September 2010), pp. 526-533, PMID: 19450997. 
Shemtov, MM.; Cheng, D.L.; Kong, L.; Shu, W.P.; Sassaroli, M.; Droller, M.J. & Liu, B.C. 
(1995). LAK cell mediated apoptosis of human bladder cancer cells involves a pH-
dependent endonuclease system in the cancer cell: possible mechanism of BCG 
therapy. J. Urol., Vol. 154, No. 1, (July 1995), pp. 269-274, PMID: 7776443. 
Shen, H.; Wang, C.; Yang, E.; Xu, Y.; Liu, W.; Yan, J.; Wang, F. & Wang, H. (2010). Novel 
recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-alpha induces 
significantly enhanced cellular immune and antibody responses in C57BL/6 mice. 
Microbiol. Immunol., Vol. 54, No. 8, (August 2010), pp. 435-441, PMID: 20646207. 
Simons, M.P.; O'Donnell, M.A. & Griffith, T.S. (2008). Role of neutrophils in BCG 
immunotherapy for bladder cancer. Urol. Oncol., Vol. 26, No. 4, (July 2008), pp. 341-
345, PMID: 18593617. 
Slobbe, L.; Lockhart, E,; O'Donnell, M.A.; MacKintosh, C.; De Lisle, G. & Buchan, G. (1999). 
An in vivo comparison of bacillus Calmette-Guérin (BCG) and cytokine-secreting 
BCG vaccines. Immunology, Vol. 96, No. 4, (April 1999), pp. 517-523, PMID: 
10233736. 
Snapper, S.B.; Lugosi, L.; Jekkel, A.; Melton, R.E.; Kieser, T.; Bloom, B.R. & Jacobs, W.R. Jr. 
(1988). Lysogeny and transformation in mycobacteria: stable expression of foreign 
www.intechopen.com
 
Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
88
genes. Proc. Natl. Acad. Sci. USA, Vol. 85, No. 18, (September 1988), pp. 6987-6991, 
PMID: 2842799. 
Soualhine, H.; Deghmane, A.E.; Sun, J.; Mak, K.; Talal, A.; Av-Gay, Y. & Hmama, Z. (2007). 
Mycobacterium bovis bacillus Calmette-Guérin secreting active cathepsin S 
stimulates expression of mature MHC class II molecules and antigen presentation 
in human macrophages. J. Immunol., Vol. 179, No. 8, (October 2007), pp. 5137-5145, 
PMID: 17911599. 
Stavropoulos, N.E.; Hastazeris, K.; Filiadis, I.; Mihailidis, I.; Ioachim, E.; Liamis, Z. & 
Kalomiris, P. (2002). Intravesical instillations of interferon gamma in the 
prophylaxis of high risk superficial bladder cancer--results of a controlled 
prospective study. Scand. J. Urol. Nephrol., Vol. 36, No. 3, (2002), pp. 218-222, PMID: 
12201939. 
Stover, C.K.; de la Cruz, V.F.; Fuerst, T.R.; Burlein, J.E.; Benson, L.A.; Bennett, L.T.; Bansal, 
G.P.; Young, J.F.; Lee, M.H.; Hatfull, G.F.; Snapper, S.B.; Barletta, R.G.; Jacobs Jr, 
W.R. & Bloom B.R. (1991). New use of BCG for recombinant vaccines. Nature, Vol. 
351, No. 6326, (June 1991), pp. 456-460, PMID: 1904554. 
Stover, C.K.; Bansal, G.P.; Hanson, M.S.; Burlein, J.E.; Palaszynski, S.R.; Young, J.F.; Koenig, 
S.; Young, D.B.; Sadziene, A. & Barbour, A.G. (1993). Protective immunity elicited 
by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A 
(OspA) lipoprotein: a candidate Lyme disease vaccine. J. Exp. Med., Vol. 178, No. 1, 
(July 1993), pp. 197-209, PMID: 8315378. 
Stravoravdi, P.; Toliou, T.; Kirtsis, P.; Natsis, K.; Konstandinidis, E.; Barich, A.; Gigis, P. & 
Dimitriadis, K. (1999). A new approach in the management of urothelial tumors 
using GM-CSF on marker lesions: an ultrastructural and immunohistochemical 
study on the macrophage population in bladder mucosa. J. Interferon Cytokine Res., 
Vol. 19, No. 3, (March 1999), pp. 221-225, PMID: 10213460. 
Suttmann, H.; Jacobsen, M.; Reiss, K.; Jocham, D.; Böhle, A. & Brandau, S. (2004). 
Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J. 
Urol., Vol. 172, No. 4 Pt 1, (October 2004), pp. 1490-1495, PMID: 15371877. 
Suttmann, H.; Riemensberger. J.; Bentien, G.; Schmaltz, D.; Stöckle, M.; Jocham, D.; Böhle, A. 
& Brandau, S. (2006). Neutrophil granulocytes are required for effective Bacillus 
Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune 
responses. Cancer Res., Vol. 66, No. 16, (August 2006), pp. 8250-8257, PMID: 
16912205. 
Tang, C.; Yamada, H.; Shibata, K.; Maeda, N.; Yoshida, S.; Wajjwalku, W.; Ohara, N.; 
Yamada, T.; Kinoshita, T. & Yoshikai, Y. (2008). Efficacy of recombinant bacille 
Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in 
providing protection against Mycobacterium tuberculosis. J. Infect. Dis., Vol. 197, 
No. 9, (May 2008), pp. 1263-1274, PMID: 18422438. 
Taniguchi, K.; Koga, S.; Nishikido, M.; Yamashita, S.; Sakuragi, T.; Kanetake, H. & Saito, Y. 
(1999). Systemic immune response after intravesical instillation of bacille Calmett-
Guérin (BCG) for superficial bladder cancer. Clin. Exp. Immunol., Vol. 115, No. 1, 
(January 1999), pp. 131-135, PMID: 9933432. 
Theano, T.; Pelagia, S.; Konstantinos, N.; Petros, K.; Alfred, B.; Konstantinos, D. & 
Panagiotis, G. (2002). Lymphocyte activation by granulocyte macrophage-colony 
www.intechopen.com
Th1 Cytokine-Secreting Recombinant Bacillus Calmette-Guérin:  
Prospective Use in Immunotherapy of Bladder Cancer 
 
89 
stimulating factor in human bladder cancer. J. Exp. Ther. Oncol., Vol. 2, No. 3, (May 
2002), pp. 153-157, PMID: 12415631. 
Tubaro, A.; Stoppacciaro, A.; Velotti, F.; Bossola, P.C.; Cusumano, G.; Vicentini, C.; De Carli, 
P.; Ruco, L.; Santoni, A.; Cancrini, A.; et al. (1995). Local immunotherapy of 
superficial bladder cancer by intravesical instillation of recombinant interleukin-2. 
Eur. Urol., Vol. 28, No. 4, (1995), pp. 297-303, PMID: 8575496. 
Van Faassen, H.; Dudani, R.; Krishnan, L. & Sad, S. (2004). Prolonged antigen presentation, 
APC-, and CD8+ T cell turnover during mycobacterial infection: comparison with 
Listeria monocytogenes. J. Immunol., Vol. 172, No. 6, (March 2004), pp. 3491-3500, 
PMID: 15004149. 
Wangoo, A.; Brown, I.N.; Marshall, B.G.; Cook, H.T.; Young, D.B. & Shaw, R.J. (2000). Bacille 
Calmette-Guérin (BCG)-associated inflammation and fibrosis: modulation by 
recombinant BCG expressing interferon-gamma (IFN-gamma). Clin. Exp. Immunol., 
Vol. 119, No. 1, (January 2000), pp. 92-98, PMID: 10606969. 
Weiss, G.R.; O'Donnell, M.A.; Loughlin, K.; Zonno, K.; Laliberte, R.J. & Sherman, M.L. 
(2003). Phase 1 study of the intravesical administration of recombinant human 
interleukin-12 in patients with recurrent superficial transitional cell carcinoma of 
the bladder. J. Immunother., Vol. 26, No. 4, (July 2003), pp. 343-348, PMID: 12843796. 
Williams, S.K.; Hoenig, D.M.; Ghavamian, R. & Soloway, M. (2010). Intravesical therapy for 
bladder cancer. Expert Opin. Pharmacother., Vol. 11, No. 6, (April 2010), pp. 947-958, 
PMID: 20205607. 
Xu, Y.; Zhu, B.; Wang, Q.; Chen, J.; Qie, Y.; Wang, J.; Wang, H.; Wang, B. & Wang, H. (2007). 
Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers 
effective protection against Mycobacterium tuberculosis in C57BL/6 mice. FEMS 
Immunol. Med. Microbiol., Vol. 51, No. 3, (December 2007), pp. 480-487, PMID: 
17919299. 
Yamada, H.; Matsumoto, S.; Matsumoto, T.; Yamada, T. & Yamashita, U. (2000). Murine IL-2 
secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated 
cytotoxicity against murine bladder cancer MBT-2. J. Urol., Vol. 164, No. 2, (August 
2000), pp. 526-531, PMID: 10893638. 
aYoung, S.L.; O'Donnell, M.A. & Buchan, G.S. (2002). IL-2-secreting recombinant bacillus 
Calmette Guerin can overcome a Type 2 immune response and corticosteroid-
induced immunosuppression to elicit a Type 1 immune response. Int. Immunol., 
Vol. 14, No. 7, (July 2002), pp. 793-800, PMID: 12096039. 
bYoung, S.; O'Donnell, M.; Lockhart, E.; Buddle, B.; Slobbe, L.; Luo, Y.; De Lisle, G. & 
Buchan, G. (2002). Manipulation of immune responses to Mycobacterium bovis by 
vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin. 
Immunol. Cell Biol., Vol. 80, No. 3, (June 2002), pp. 209-215, PMID: 12067407. 
Young, S.L.; Murphy, M.; Zhu, X.W.; Harnden, P.; O'Donnell, M.A.; James, K.; Patel, P.M.; 
Selby, P.J. & Jackson, A.M. (2004). Cytokine-modified Mycobacterium smegmatis as 
a novel anticancer immunotherapy. Int. J. Cancer, Vol. 112, No. 4, (November 2004), 
pp. 653-660, PMID: 15382047. 
aYuan, S.; Shi, C.; Han, W.; Ling, R.; Li, N. & Wang, T. (2009). Effective anti-tumor responses 
induced by recombinant bacillus Calmette-Guérin vaccines based on different 
tandem repeats of MUC1 and GM-CSF. Eur. J. Cancer Prev., Vol. 18, No. 5, 
(September 2009), pp. 416-423, PMID:19550341. 
www.intechopen.com
 
Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
90
bYuan, S.; Shi, C.; Lv, Y.; Wang, T.; Wang, H. & Han, W. (2009). A novel Bacillus Calmette-
Guérin-based breast cancer vaccine that coexpresses multiple tandem repeats of 
MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast 
cancer growth. Cancer Biother. Radiopharm., Vol. 24, No. 5, (October 2009), pp. 607-
613, PMID: 19877891. 
Yuan, S.; Shi, C.; Ling, R.; Wang, T.; Wang, H. & Han, W. (2010). Immunization with two 
recombinant Bacillus Calmette-Guérin vaccines that combine the expression of 
multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast 
tumor growth in mice. J. Cancer Res. Clin. Oncol., Vol. 136, No. 9, (September 2010), 
pp. 1359-1367, PMID: 20127358. 
Zaharoff, D.A.; Hoffman, B.S.; Hooper, H.B.; Benjamin, C.J. Jr., Khurana, K.K.; Hance, K.W.; 
Rogers, C.J.; Pinto, P.A.; Schlom, J. & Greiner, J.W. (2009). Intravesical 
immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer 
Res., Vol. 69, No. 15, (August 2009), pp. 6192-6199, PMID: 19638573. 
Zhang, G.; Chen, F.; Cao, Y. & See, W.A. (2007). Bacillus Calmette-Guérin induces p21 
expression in human transitional carcinoma cell lines via an immediate early, p53 
independent pathway. Urol. Oncol., Vol. 25, No. 3, (May 2007), pp. 221-227, PMID: 
17483019.  
www.intechopen.com
Current Cancer Treatment - Novel Beyond Conventional
Approaches
Edited by Prof. Oner Ozdemir
ISBN 978-953-307-397-2
Hard cover, 810 pages
Publisher InTech
Published online 09, December, 2011
Published in print edition December, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Currently there have been many armamentaria to be used in cancer treatment. This indeed indicates that the
final treatment has not yet been found. It seems this will take a long period of time to achieve. Thus, cancer
treatment in general still seems to need new and more effective approaches. The book "Current Cancer
Treatment - Novel Beyond Conventional Approaches", consisting of 33 chapters, will help get us physicians as
well as patients enlightened with new research and developments in this area. This book is a valuable
contribution to this area mentioning various modalities in cancer treatment such as some rare classic
treatment approaches: treatment of metastatic liver disease of colorectal origin, radiation treatment of skull
and spine chordoma, changing the face of adjuvant therapy for early breast cancer; new therapeutic
approaches of old techniques: laser-driven radiation therapy, laser photo-chemotherapy, new approaches
targeting androgen receptor and many more emerging techniques.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Yi Luo, Jonathan Henning and Michael A. O’Donnell (2011). Th1 Cytokine-Secreting Recombinant Bacillus
Calmette-Gue ́rin: Prospective Use in Immunotherapy of Bladder Cancer, Current Cancer Treatment - Novel
Beyond Conventional Approaches, Prof. Oner Ozdemir (Ed.), ISBN: 978-953-307-397-2, InTech, Available
from: http://www.intechopen.com/books/current-cancer-treatment-novel-beyond-conventional-approaches/th1-
cytokine-secreting-recombinant-bacillus-calmette-gue-rin-prospective-use-in-immunotherapy-of-bla
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
